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Labeled
• cytokine release syndrome
• polyarticular juvenile idiopathic arthritis
• rheumatoid arthritis
• systemic juvenile idiopathic arthritis
• temporal arteritis
Off-Label
• coronavirus disease 2019 (COVID-19) †
• scleroderma (systemic sclerosis) †
• severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection †
† Off-label indication
For the treatment of moderately- to severely-active rheumatoid arthritis in patients who 
have had an inadequate response to one or more disease-modifying antirheumatic drugs
Intravenous dosage
• Adults
4 mg/kg IV infusion given over 1 hour every 4 weeks. May increase dose to 8 mg/kg IV every 4 weeks if
needed; doses greater than 800 mg per infusion are not recommended. May use as monotherapy or
concomitantly with methotrexate or other non-biologic DMARDs. Avoid concurrent use with biological
DMARDs such as tumor necrosis factor (TNF) modifiers, anakinra, rituximab, ofatumumab, and abatacept.
[38283]
Subcutaneous dosage
• Adults weighing less than 100 kg
162 mg subcutaneously every other week as monotherapy or concomitantly with methotrexate or other non-
biologic DMARDs. Increase to 162 mg subcutaneously once weekly based on clinical response. If transitioning
from IV tocilizumab, give the first subcutaneous dose instead of the next scheduled IV dose.[38283]
• Adults weighing 100 kg or more
162 mg subcutaneously once weekly as monotherapy or concomitantly with methotrexate or other non-
biologic DMARDs. If transitioning from IV tocilizumab, give the first subcutaneous dose instead of the next
scheduled IV dose.[38283]
INVESTIGATIONAL USE: For adjunctive use in the treatment of severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection†, the virus that causes 
coronavirus disease 2019 (COVID-19)†
Intravenous dosage
• Adults
Available data are limited, and efficacy has not been established. Due to a lack of clinical data, the National 
Institutes of Health (NIH) COVID-19 treatment guidelines do not recommend for or against the use of IL-6 
receptor inhibitors, such as tocilizumab.[65314] 4 to 8 mg/kg/dose (Usual dose: 400 mg; Max dose: 800 mg) IV 
once is being evaluated in combination with antiviral therapy.[65148] [65162] [65163] [65191] [65193] [65194] A 
second dose administered 8 to 12 hours after the first infusion may be considered in patients who show a lack 
of clinical response (i.e., continued fever).[65148] [65163] [65193] One protocol suggests a possible third dose 
administered 16 to 24 hours after the first dose.[65148]
For the treatment of active polyarticular juvenile idiopathic arthritis
NOTE: Tocilizumab has been designated an orphan drug by the FDA for this indication.
Intravenous dosage
• Children and Adolescents 2 to 17 years weighing 30 kg or more
8 mg/kg/dose IV every 4 weeks; administer over 1 hour. Do not change dose based solely on a single visit 
body weight measurement, as weight may fluctuate. May use as monotherapy or in combination with 
methotrexate.[38283]
• Children and Adolescents 2 to 17 weighing less than 30 kg
10 mg/kg/dose IV every 4 weeks; administer over 1 hour. Do not change dose based solely on a single visit 
body weight measurement, as weight may fluctuate. May use as monotherapy or in combination with 
methotrexate.[38283]
Subcutaneous dosage
• Children and Adolescents 2 to 17 years weighing 30 kg or more
162 mg/dose subcutaneously every 2 weeks. When transitioning from IV to subcutaneous administration, 
administer the first subcutaneous dose instead of the next scheduled IV dose. Do not change dose based 
solely on a single visit body weight measurement, as weight may fluctuate. May use as monotherapy or in 
combination with methotrexate.[38283]
• Children and Adolescents 2 to 17 years weighing less than 30 kg
162 mg/dose subcutaneously every 3 weeks. When transitioning from IV to subcutaneous administration, 
administer the first subcutaneous dose instead of the next scheduled IV dose. Do not change dose based 
solely on a single visit body weight measurement, as weight may fluctuate. May use as monotherapy or in 
combination with methotrexate.[38283]
For the treatment of active systemic juvenile idiopathic arthritis
Intravenous dosage
• Children and Adolescents 2 to 17 years weighing 30 kg or more
8 mg/kg/dose IV every 2 weeks; administer over 1 hour. Do not change dose based solely on a single visit 
body weight measurement, as weight may fluctuate. May use as monotherapy or in combination with 
methotrexate.[38283]
• Children and Adolescents 2 to 17 years weighing less than 30 kg
12 mg/kg/dose IV every 2 weeks; administer over 1 hour. Do not change dose based solely on a single visit 
body weight measurement, as weight may fluctuate. May use as monotherapy or in combination with 
methotrexate.[38283]
Subcutaneous dosage
• Children and Adolescents 2 to 17 years weighing 30 kg or more
162 mg/dose subcutaneously every week. When transitioning from IV to subcutaneous administration, 
administer the first subcutaneous dose instead of the next scheduled IV dose. Do not change dose based 
solely on a single visit body weight measurement, as weight may fluctuate. May use as monotherapy or in 
combination with methotrexate.[38283]
• Children and Adolescents 2 to 17 years weighing less than 30 kg
162 mg/dose subcutaneously every 2 weeks. When transitioning from IV to subcutaneous administration, 
administer the first subcutaneous dose instead of the next scheduled IV dose. Do not change dose based 
solely on a single visit body weight measurement, as weight may fluctuate. May use as monotherapy or in 
combination with methotrexate.[38283]
For the treatment of systemic scleroderma (systemic sclerosis)†
Strength of Recommendation: Equivocal/Weak For
Level of Evidence: Very Low, Detailed Level of Evidence
NOTE: Tocilizumab has been designated an orphan drug by the FDA for this indication.  
Intravenous dosage
• Adults
8 mg/kg IV once monthly.[62882]
Subcutaneous dosage
• Adults
162 mg subcutaneously once weekly.[62883]
For the treatment of temporal arteritis, also known as giant cell arteritis (GCA)
Subcutaneous dosage
• Adults
162 mg subcutaneously once weekly, in combination with a tapering course of glucocorticoids, is the 
recommended dose. A dose of 162 mg subcutaneously once every other week, in combination with a tapering 
course of glucocorticoids, may be prescribed based on clinical considerations. Tocilizumab may be used alone 
following discontinuation of glucocorticoids.[38283]
For the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-
threatening cytokine release syndrome (CRS)
Intravenous dosage
• Adults, Adolescents, and Children 2 years old and older, weighing 30 kg or more
8 mg/kg IV over 60 minutes for one dose, alone or in combination with corticosteroids. If no clinical 
improvement in the signs and symptoms of CRS occur after the first dose, up to 3 additional doses of 
tocilizumab may be administered at least 8 hours apart; doses exceeding 800 mg are not recommended. Only 
the intravenous route should be used for the treatment of CRS; subcutaneous administration is not approved 
for this use. In a retrospective analysis of pooled outcome data from clinical trials of CAR T-cell therapies for 
hematologic malignancies, 69% of patients with a first episode of CRS who were treated with tocilizumab 
achieved a response, defined as resolution (lack of fever and off vasopressors for at least 24 hours) within 14 
days of the first dose of tocilizumab, less than 2 doses of tocilizumab administered, and no additional 
treatment beyond tocilizumab and corticosteroids. This was confirmed in a second study using an independent 
cohort that included 14 patients with CAR T cell-induced CRS.[38283]
• Adults, Adolescents, and Children 2 years old and older, weighing less than 30 kg
12 mg/kg IV infusion over 60 minutes for one dose, alone or in combination with corticosteroids. If no clinical 
improvement in the signs and symptoms of CRS occur after the first dose, up to 3 additional doses of 
tocilizumab may be administered at least 8 hours apart; doses exceeding 800 mg are not recommended. Only 
the IV route should be used for the treatment of CRS; subcutaneous administration is not approved for this 
use. In a retrospective analysis of pooled outcome data from clinical trials of CAR T-cell therapies for 
hematologic malignancies, 69% of patients with a first episode of CRS who were treated with tocilizumab 
achieved a response, defined as resolution (lack of fever and off vasopressors for at least 24 hours) within 14 
days of the first dose of tocilizumab, less than 2 doses of tocilizumab administered, and no additional 
treatment beyond tocilizumab and corticosteroids. This was confirmed in a second study using an independent 
cohort that included 14 patients with CAR T cell-induced CRS.[38283]
Therapeutic Drug Monitoring
Prior to initiation of treatment
Check the patient's ANC, platelet count, and liver function tests (ALT/AST concentrations) before tocilizumab 
initiation. In adults, tocilizumab is not recommended for patients with an ANC less than 2,000/mm3, a platelet count 
less than 100,000/mm3, or an ALT or AST greater than 1.5 times the upper limit of normal (ULN). In patients with 
severe or life-threatening cytokine releasing syndrome (CRS) who also have cytopenias and/or elevated hepatic 
enzymes due to lymphodepleting chemotherapy or the CRS, consider the potential benefit of treating the CRS versus 
the risks of short-term treatment with tocilizumab.[38283]
Dosage modifications for adult patients with rheumatoid arthritis or giant cell arteritis
Absolute neutrophil count (ANC) 500 to 1,000 cells/mm3: Hold tocilizumab and restart when ANC more than 1,000 
cells/mm3 with IV dosing at 4 mg/kg with an increase to 8 mg/kg as clinically appropriate or subcutaneous dosing at 
every other week with an increase to weekly as clinically appropriate.
Absolute neutrophil count (ANC) less than 500 cells/mm3: Discontinue tocilizumab.
Platelet count 50,000 to 100,000 cells/mm3: Hold tocilizumab and restart when platelet count is greater than 
100,000/mm3 with IV dosing at 4 mg/kg with an increase to 8 mg/kg as clinically appropriate or subcutaneous dosing 
at every other week with an increase to weekly as clinically appropriate.
Platelet count less than 50,000 cells/mm3: Discontinue tocilizumab.
Hepatic enzyme abnormalities: Dosage interruption or modifications are recommended based on the degree of 
abnormality occurring during treatment, as evidenced by the degree of AST/ALT elevations above the upper limit of 
normal (ULN).[38283]
Pediatric Patients
• Tocilizumab dose reduction has not been studied in the systemic juvenile idiopathic arthritis (SJIA) or 
polyarticular juvenile idiopathic arthritis (PJIA) population.
• Tocilizumab dose interruptions are recommended for low neutrophil counts and low platelet counts in 
patients with SJIA or PJIA at levels similar to what is outlined for adult patients with rheumatoid arthritis. 
If appropriate, concomitant methotrexate and/or other medications should be dose modified or stopped and 
tocilizumab dosing interrupted until the clinical situation has been evaluated. In SJIA and PJIA, base the 
decision to discontinue tocilizumab for a laboratory abnormality upon the medical assessment of the 
individual patient.[38283]
Maximum Dosage Limits
• Adults 
Rheumatoid arthritis, weighing more than 100 kg: 800 mg/dose IV and 162 mg/dose subcutaneously.
Rheumatoid arthritis and giant cell arteritis, weighing 100 kg or less: 8 mg/kg/dose IV and 162 mg/dose 
subcutaneously.
Cytokine Release Syndrome (CRS), weighing 30 kg or more: 800 mg/dose IV.
CRS, weighing less than 30 kg: 12 mg/kg IV.
• Geriatric 
Rheumatoid arthritis, weighing more than 100 kg: 800 mg/dose IV and 162 mg/dose subcutaneously.
Rheumatoid arthritis and giant cell arteritis, weighing 100 kg or less: 8 mg/kg/dose IV and 162 mg/dose 
subcutaneously.
Cytokine Release Syndrome (CRS), weighing 30 kg or more: 800 mg/dose IV.
CRS, weighing less than 30 kg: 12 mg/kg IV.
• Adolescents 
Weighing 30 kg or more: 8 mg/kg/dose IV and 162 mg/dose subcutaneously.
Weighing less than 30 kg: 12 mg/kg/dose IV for systemic juvenile idiopathic arthritis (SJIA) and cytokine 
release syndrome (CRS); 10 mg/kg/dose IV for polyarticular juvenile idiopathic arthritis (PJIA); 162 
mg/dose subcutaneously for SJIA and PJIA.
• Children 
2 to 12 years weighing 30 kg or more: 8 mg/kg/dose IV and 162 mg/dose subcutaneously.
2 to 12 years weighing less than 30 kg: 12 mg/kg/dose IV for systemic juvenile idiopathic arthritis (SJIA) 
and cytokine release syndrome (CRS); 10 mg/kg/dose IV for polyarticular juvenile idiopathic arthritis 
(PJIA); 162 mg/dose subcutaneously for SJIA and PJIA.
Younger than 2 years: Safety and efficacy have not been established.
• Infants 
Safety and efficacy have not been established.
Patients with Hepatic Impairment Dosing
Prior to treatment initiation
Do not initiate treatment with tocilizumab if active liver disease or hepatic impairment is present, or if baseline 
AST/ALT is more than 1.5 times the upper limit of normal (ULN). However, patients with severe or life-threatening 
cytokine release syndrome (CRS) frequently have elevated ALT or AST; the decision to administer tocilizumab 
should take into account the potential benefit of treating the CRS versus the risks of short-term treatment with 
tocilizumab.[38283]
Hepatic enzyme elevations that occur during treatment
Adult Patients with rheumatoid arthritis or giant cell arteritis with hepatic impairment[38283]
AST and/or ALT of more than 1 times and up to 3 times the ULN:
• Dose modify concomitant DMARDs, if appropriate.
• For persistent increases in this range:
◦ Intravenous dosing: For persistent increases in this range, reduce IV tocilizumab dose to 4 
mg/kg or hold tocilizumab dosing until AST and/or ALT have normalized.
◦ Subcutaneous dosing: Reduce subcutaneous dosing interval to every other week or hold 
tocilizumab dosing until AST and/or ALT have normalized. Once ALT and/or AST have 
normalized, resume subcutaneous injection at every other week dosing and increase to once 
weekly as clinically appropriate.
AST and/or ALT more than 3 times and up to 5 times the ULN:
• Interrupt tocilizumab dosing until AST and/or ALT is less than 3 times the ULN and then follow dosing 
recommendations for AST and/or ALT more than 1 to 3 times ULN.
• For persistent increases of more than 3 times the ULN, discontinue tocilizumab.
AST and/or ALT greater than 5 times the ULN: Discontinue tocilizumab.
-Pediatric Patients with hepatic impairment[38283]
Tocilizumab dose reduction has not been studied in the systemic juvenile idiopathic arthritis (SJIA) or polyarticular 
juvenile idiopathic arthritis (PJIA) population. Tocilizumab dose interruptions are recommended for liver enzyme 
abnormalities in patients with SJIA or PJIA at levels similar to what is outlined for adult patients with rheumatoid 
arthritis and giant cell arteritis. If appropriate, adjust or stop concomitant DMARDs and hold tocilizumab dosing until 
the clinical situation has been evaluated. In SJIA and PJIA, base the decision to discontinue tocilizumab upon the 
medical assessment of the individual patient and the laboratory abnormality involved.
Patients with Renal Impairment Dosing
CrCl 30 mL/minute or more: No dosage adjustment is needed.
CrCl less than 30 mL/minute: Tocilizumab has not been studied in patients with severe renal impairment.[38283]
† Off-label indication
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How Supplied
Tocilizumab Solution for injection
Actemra 200mg/10mL Solution for Injection (50242-0136) (Genentech Inc) 
Actemra 400mg/20mL Solution for Injection (50242-0137) (Genentech Inc) 
Actemra 80mg/4mL Solution for Injection (50242-0135) (Genentech Inc) 
Actemra 162mg/0.9mL Solution for Injection (50242-0138) (Genentech Inc) 
Actemra ACTPen 162mg/0.9mL Solution for Injection (50242-0143) (Genentech Inc) 
Description/Classification
Description
Tocilizumab is a humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody produced in mammalian 
(Chinese hamster ovary) cells. In patients with inflammatory diseases such as rheumatoid arthritis, IL-6 
concentrations correlate with disease activity and joint or tissue damage. In adults, tocilizumab is FDA approved for 
the treatment of moderate to severe rheumatoid arthritis (RA) after inadequate response to disease-modifying 
antirheumatic drugs (DMARDs).[38283] In adults with rheumatoid arthritis (RA) tocilizumab improves clinical signs 
and symptoms, inhibits the radiographic progression of structural joint damage, and improves health status. In 
pediatric patients 2 years of age and older, tocilizumab is approved for polyarticular and systemic juvenile idiopathic 
arthritis (pJIA and sJIA).[38283] In adult and pediatric patients with inflammatory arthritis conditions, tocilizumab is 
often considered as an alternative to TNF-blockers or may be used when TNF-blockers have failed to produce 
adequate responses.[56233][61404] For RA, pJIA, and sJIA, tocilizumab may be used alone or in combination with 
methotrexate; in treating adult RA, other non-biologic DMARDs may also be used concurrently.[38283] The ideal 
combination of therapy for individual patients with inflammatory arthritis conditions is determined by treat to target 
strategies and severity of disease.[56233][61404] In adults, tocilizumab has proven effective for giant cell arteritis 
(GCA or temporal arteritis), where it is used initially with a tapering dose of corticosteroids.[38283] Additionally, the 
drug is approved in adult and pediatric patients 2 years and older for cytokine release syndrome (CRS) due to 
chimeric antigen receptor (CAR) T cell treatment.[38283] Tocilizumab labeling carries a boxed warning regarding the 
risk for serious infections that may lead to hospitalization or death; live vaccines should not be administered with 
tocilizumab. Severe hypersensitivity reactions, including anaphylaxis and death, have also been reported with 
tocilizumab therapy.[38283]
Updates for coronavirus disease 2019 (COVID-19):
Available data are limited. Due to a lack of clinical data, the National Institutes of Health (NIH) COVID-19 treatment 
guidelines do not give recommendations for or against the use of IL-6 receptor inhibitors, such as tocilizumab.[65314]
Preliminary data suggest tocilizumab may have clinical benefit as adjunctive therapy in the treatment of COVID-19 
due to SARS-CoV-2. In a retrospective review of 21 patients, tocilizumab was added to standard therapy. Clinical 
symptoms, CT opacity changes, lymphocyte percentage, and C-reactive protein levels all improved in these patients; 
however, no comparators were reported.[65162] Additional data regarding clinical efficacy for COVID-19 are being 
evaluated.[65148][65163][65191][65193][65194]
Classifications
• Antineoplastic and Immunomodulating Agents
◦ Agents that Suppress the Immune System
◾ Interleukin-6 (IL-6) Inhibitors
• Musculo-Skeletal System
◦ Antiinflammatory Agents and Antirheumatic Agents
◾ Specific Anti-Rheumatic Agents
◾ Anti-Rheumtic Monoclonal Antibodies
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Administration Information
General Administration Information
For storage information, see the specific product information within the How Supplied section.
Route-Specific Administration
Injectable Administration
• Visually inspect parenteral products for particulate matter and discoloration prior to administration 
whenever solution and container permit. Tocilizumab is a clear and colorless to pale yellow liquid.
• The prefilled syringe and the autoinjector are ONLY for subcutaneous injection use.
• The vial is ONLY for use in preparing an intravenous infusion.[38283]
Intravenous Administration
• Administer intravenous infusions under the supervision of a qualified health professional. Have 
appropriate medical treatment available for immediate use in the event of a serious hypersensitivity 
reaction.
• The drug must be diluted as an infusion prior to use. Do not administer as an intravenous push or bolus.
[38283]
Infusion Preparation
• Compatible infusion solutions for preparation: 0.9% Sodium Chloride Injection or 0.45% Sodium 
Chloride Injection.
• Utilize a 50 mL infusion bag or bottle for patients who weigh less than 30 kg. Utilize a 100 mL infusion 
bag or bottle for patients who weigh at least 30 kg.
• From a 50 mL or 100 mL infusion bag or bottle, withdraw a volume of the 0.9% Sodium Chloride 
Injection or 0.45% Sodium Chloride Injection equal to the volume of the tocilizumab solution required for 
the patient's dose.
• Each tocilizumab vial contains a 20 mg/mL solution.
◦ For a 4 mg/kg dose, 0.2 mL/kg of tocilizumab is needed.
◦ For a 8 mg/kg dose, 0.4 mL/kg is needed.
◦ For a 10 mg/kg dose, 0.5 mL/kg is needed.
◦ For a 12 mg/kg dose, 0.6 mL/kg is needed.
• Withdraw the amount of tocilizumab for intravenous infusion from the vial(s) and slowly add to the 
infusion bag or bottle.
• Gently invert the bag to mix and to avoid foaming.
• Fully diluted tocilizumab solutions are compatible with polypropylene, polyethylene, and polyvinyl 
chloride infusion bags and polypropylene, polyethylene, and glass infusion bottles.
• Storage: The fully diluted tocilizumab solutions for infusion using 0.9% Sodium Chloride Injection may 
be stored at 2 to 8 degrees C (36 to 46 degrees F) or room temperature for up to 24 hours and should be 
protected from light. The fully diluted tocilizumab solutions for infusion using 0.45% Sodium Chloride 
Injection may be stored at 2 to 8 degrees C (36 to 46 degrees F) for up to 24 hours or at room temperature 
for up to 4 hours and should be protected from light. Do not freeze.
• Do not use any unused product remaining in vials; tocilizumab does not contain preservatives.[38283]
Intravenous Infusion Administration
• Prior to infusion, allow the fully diluted tocilizumab infusion to reach room temperature.
• Administer as an intravenous infusion over 60 minutes with an infusion set.
• Do not infuse tocilizumab concomitantly in the same intravenous line with other drugs. No physical or 
biochemical compatibility studies have been conducted to evaluate the coadministration of tocilizumab 
with other drugs.[38283]
Subcutaneous Administration
General information
• Administer the first injection of tocilizumab under the supervision of a qualified health professional. Have 
appropriate medical treatment available for immediate use in the event of a serious hypersensitivity 
reaction.
• Assess the suitability of the patient for home use after the first dose. Patients should inform their provider 
before administering the next dose if they experience any symptoms of an allergic reaction. Patients 
should seek immediate medical attention if they develop symptoms of serious allergic reactions.
• After the first dose, the subcutaneous injection may subsequently be given by the patient or patient's 
caregiver after proper training in injection technique, and a healthcare practitioner determines that it is 
appropriate.
• Pediatric patients may self-inject with the prefilled syringe if both the healthcare practitioner and the 
parent/legal guardian determines it is appropriate. The ability of pediatric patients to self-inject using the 
autoinjector has not been tested.[38283]
Prefilled Syringe:
• Remove the prefilled syringe from the refrigerator and allow it to sit at room temperature outside of the 
carton for 30 minutes. Do not warm tocilizumab in any other way.
• Pick an injection site such as the front of a thigh, the outer area of an upper arm, or the abdomen except 
for the 2-inch area around the navel. Do not inject into moles, scars, or areas where the skin is tender, 
bruised, red, hard, or not intact.
• Rotate injection sites with each injection. Inject at least 1 inch from the last area injected.
• Remove the needle cap immediately before injection, and gently pinch a cleaned area of skin. Using a 
dart-like motion, insert the needle at a 45-degree or 90-degree angle. Release the pinched skin, and gently 
push the plunger all the way down to inject the full amount in the prefilled syringe (0.9 mL), which 
provides 162 mg of tocilizumab.
• The prefilled syringe is for single-use only, as it does not have a preservative.
• Remove the needle from the skin while continuing the depress the plunger. After the needle is completely 
removed, release the plunger, which will allow the needle-shield to protect the needle. Do not rub the 
injection site.
• Dispose of needles and syringes in an FDA-cleared sharps disposal container right away after use.[38283]
Autoinjector:
• Remove the autoinjector from the refrigerator and allow it to sit at room temperature outside of the carton 
for 45 minutes. Do not warm tocilizumab in any other way.
• Pick an injection site such as the front of a thigh, the outer area of an upper arm, or the abdomen except 
for the 2-inch area around the navel. Do not inject into moles, scars, or areas where the skin is tender, 
bruised, red, hard, or not intact.
• Do not auto inject through clothing.
• Rotate injection sites with each injection. Inject at least 1 inch from the last area injected.
• Remove the needle cap immediately before injection, and gently pinch a cleaned area of skin. Place the 
needle-shield at a 90-degree angle against the pinched skin.
• Unlock the green activation button by firmly pressing the autoinjector against the pinched skin, then press 
the green button to start the injection. Continue to hold the autoinjector firmly against the skin until the 
purple indicator stops moving and the full dose administered; the complete injection may take up to 10 
seconds.
• Release the green button and lift autoinjector off the skin at a 90-degree angle.
• The autoinjector is for single-use only, as it does not have a preservative. Dispose of needles and syringes 
in an FDA-cleared sharps disposal container right away after use.[38283]
Clinical Pharmaceutics Information
From Trissel's 2™ Clinical Pharmaceutics Database 
Tocilizumab
1. pH Range
pH near 6.5 (vial). pH near 6.0 (prefilled syringe)
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Adverse Reactions
• abdominal pain
• anaphylactic shock
• anaphylactoid reactions
• angioedema
• antibody formation
• arthralgia
• candidiasis
• cough
• diarrhea
• dizziness
• dyspnea
• elevated hepatic enzymes
• fatigue
• gastritis
• GI perforation
• headache
• hepatic failure
• hepatitis
• hepatotoxicity
• hypercholesterolemia
• hyperlipidemia
• hypertension
• hypertriglyceridemia
• hypotension
• infection
• infusion-related reactions
• injection site reaction
• jaundice
• macrophage activation syndrome
• neutropenia
• new primary malignancy
• optic neuritis
• oral ulceration
• pancreatitis
• peripheral neuropathy
• pharyngitis
• pruritus
• rash
• Stevens-Johnson syndrome
• thrombocytopenia
• urticaria
• visual impairment
• weakness
Tocilizumab recipients are at increased risk for developing serious infections that may lead to hospitalization or 
death. Severe and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, protozoal, or 
other opportunistic pathogens have been reported in patients receiving immunosuppressive agents including 
tocilizumab. During and after treatment with tocilizumab, closely monitor all patients for the development of signs 
and symptoms of infection including the possible development of tuberculosis (TB) in patients who tested negative 
for latent TB infection before tocilizumab use. If a serious infection develops, interrupt tocilizumab until the infection 
is controlled. Carefully consider the risks and benefits of continued tocilizumab therapy in patients with chronic or 
recurrent infection.[38283] Infections of various types were reported during clinical trials with tocilizumab. Upper 
respiratory tract infection occurred in 7% of rheumatoid arthritis patients receiving tocilizumab 8 mg/kg, in 6% of 
those receiving tocilizumab 4 mg/kg plus DMARDs, and in 8% of patients who received tocilizumab 8 mg/kg plus 
DMARDs. Naso-pharyngitis was reported in 4% to 7% of patients, and bronchitis was reported in 3% to 4% of 
patients. The rate of serious infections in the adult tocilizumab 4 mg/kg plus DMARD group was 4.4 events per 100 
patient-years, and in the 8 mg/kg plus DMARD group, the rate was 5.3 events per 100 patient-years. Among pediatric 
patients who received tocilizumab, the rate of serious infections was 11.5 per 100 patient-years for those with 
systemic juvenile idiopathic arthritis (JIA), 12.2 per 100 patient-years for those with polyarticular JIA and weight less 
than 30 kg, and 4 per 100 patient-years for those with polyarticular JIA and a weight of 30 kg or more. There is an 
overall higher incidence of infections in patients with giant cell arteritis (GCA) compared to those with rheumatoid 
arthritis. The rate of infection or serious infection was 200.2/9.7 events per 100 patient-years in the weekly 
tocilizumab group and 160.2/4.4 events per 100 patient-years in the tocilizumab every other week group compared to 
156/4.2 events per 100 patient-years in the placebo group receiving a 26-week prednisone taper and 210.2/12.5 events 
per 100 patient-years in the placebo group receiving a 52-week prednisone taper. The rate of serious infections in a 
cardiovascular outcomes study was 4.5 per 100 patient-years with tocilizumab 8 mg/kg IV, with or without 
DMARDs, every 4 weeks compared to 3.2 per 100 patient-years with etanercept 50 mg subcutaneously, with or 
without DMARDs. During clinical trials for any indication, the most common serious infections included pneumonia, 
urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, otitis media, and bacterial 
arthritis. Among opportunistic infections, tuberculosis (pulmonary or extrapulmonary disease), cryptococcus 
infection, aspergillosis, candidiasis, and pneumocystosis were reported with tocilizumab. Patients who presented with 
disseminated rather than localized disease and were often taking concomitant immunosuppressants such as 
methotrexate or corticosteroids. Viral reactivation has been reported with immunosuppressive biologic therapies and 
cases of herpes zoster exacerbation were observed in tocilizumab clinical studies. No cases of hepatitis B reactivation 
were observed in the trials; however, patients who screened positive for hepatitis were excluded.[38283]
Gastrointestinal perforation primarily as a complication of diverticulitis was reported in clinical trials. The overall 
rate of GI perforation with IV tocilizumab was 0.26 events per 100 patient years. Most patients who developed 
gastrointestinal perforations were taking concomitant nonsteroidal anti-inflammatory drugs, corticosteroids, or 
methotrexate. The relative contribution of tocilizumab to the development of gastrointestinal perforations is 
unknown. Upper abdominal pain occurred in 2% of 288 patients who got tocilizumab 8 mg/kg, in 3% of 774 patients 
who got tocilizumab 4 mg/kg plus DMARDS, and in 3% of 1582 patients who got tocilizumab 8 mg/kg plus 
DMARDS. Gastritis occurred in 1% of 288 patients who got tocilizumab 8 mg/kg, in 1% of 774 patients who got 
tocilizumab 4 mg/kg plus DMARDS, and in 2% of 1582 patients who got tocilizumab 8 mg/kg plus DMARDS. Oral 
ulceration occurred in 2% of 288 patients who got tocilizumab 8 mg/kg, in 1% of 774 patients who got tocilizumab 4 
mg/kg plus DMARDS, and in 2% of 1582 patients who got tocilizumab 8 mg/kg plus DMARDS. Use tocilizumab 
cautiously in patients who may be at increased risk for gastrointestinal perforation. Promptly evaluate patients 
presenting with new onset abdominal symptoms for early identification of gastrointestinal perforation.[38283]
Tocilizumab may cause neutropenia, and patient's neutrophil counts need to be assessed before and during drug 
receipt. In the 6-month, controlled clinical studies for rheumatoid arthritis, decreases in neutrophil counts below 
1,000/mm3 occurred in 1.8% of patients who received tocilizumab 4 mg/kg/dose and in 3.4% of patients who 
received tocilizumab 8 mg/kg/dose as compared with 0.1% of patients who received placebo. Decreases in neutrophil 
counts below 500/mm3 occurred in 0.4% of patients who received tocilizumab 4 mg/kg/dose and in 0.3% of patients 
who received tocilizumab 8 mg/kg/dose as compared with 0.1% of patients who received placebo. Approximately 
half of the instances of absolute neutrophil count (ANC) below 1,000/mm3 occurred within 8 weeks of starting 
tocilizumab. After subcutaneous tocilizumab receipt, 2.9% to 3.7% of tocilizumab recipients had a neutrophil count 
below 1,000/mm3. Among pediatric patients with polyarticular juvenile idiopathic arthritis (PJIA), 3.7% receiving IV 
treatment and 15.4% receiving subcutaneous treatment had a neutrophil count below 1,000/mm3 whereas 7% of 
patients with systemic juvenile idiopathic arthritis (SJIA) did (vs. none in the placebo group). Of note, neutropenia 
was more frequently observed in patients weighing less than 30 kg (25.9%) than those weighing 30 kg or more (4%) 
in the subcutaneous administration group. Over an average duration of 73 weeks, a decreased neutrophil count 
occurred in 17% of tocilizumab recipients. Infections have been uncommonly reported in association with treatment-
related neutropenia in long-term extension studies and postmarketing clinical experience, and no clear relationship 
between decreases in neutrophils below 1,000/mm3 and the occurrence of serious infections was noted. Among 
healthy patients who received tocilizumab 2 to 28 mg/kg/dose, the ANC nadir occurred 3 to 5 days after tocilizumab 
receipt. Neutrophils then recovered towards baseline in a dose dependent manner. A similar pattern of ANC after 
tocilizumab receipt was noted in patients with rheumatoid arthritis.[38283]
Tocilizumab may cause thrombocytopenia, and patient's platelet counts need to be assessed before and during drug 
receipt. In the 6-month, controlled clinical studies for rheumatoid arthritis, decreases in platelet counts below 
100,000/mcL occurred in 1.3% of patients who received tocilizumab 4 mg/kg and in 1.7% of patients who received 
tocilizumab 8 mg/kg as compared with 0.5% of patients who received placebo. Among patients with polyarticular 
juvenile idiopathic arthritis (PJIA), 1% had decreases in platelet count of 50,000/mcL or less. Of patients with 
systemic juvenile idiopathic arthritis (SJIA), decreases in platelet count of no more than 100,000/mcL were noted in 
1% of tocilizumab recipients and in 3% of placebo recipients at the end of the 12-week control phase. Over an 
average duration of 73 weeks, 4% of tocilizumab recipients had a decreased platelet count. Treatment-related 
reduction in platelets was not associated with serious bleeding events in clinical trials.[38283]
Serious cases of hepatotoxicity have been reported with intravenous and subcutaneous tocilizumab therapy; some of 
these cases resulted in hepatic failure, liver transplant, or death. A majority of the cases presented with elevated 
hepatic enzymes more than 5 times the upper limit of normal (ULN); however, other cases presented with mild 
elevations along with signs and symptoms of liver impairment. The time to onset ranged from weeks to years 
following initiation of tocilizumab therapy, with a median latency of 98 days. Hepatitis, drug-induced liver injury, and 
jaundice have been reported with postmarketing use of tocilizumab. Patients should have liver function tests (LFTs) 
monitored during tocilizumab treatment. Check LFTs before tocilizumab receipt, 4 to 8 weeks after the start of 
therapy for the first 6 months, and then every 3 months thereafter in adult patients. For pediatric patients with either 
polyarticular or systemic juvenile idiopathic arthritis (PJIA or SJIA), monitor LFTs at the time of the second infusion 
and then every 4 to 8 weeks for PJIA and every 2 to 4 weeks for SJIA.[38283] [65165] In the 6-month, controlled 
clinical studies for rheumatoid arthritis, 36% of patients who received tocilizumab 8 mg/kg monotherapy developed 
an ALT up to 3 times the ULN and 22% experienced AST levels up to 3 times the ULN. Increases in ALT greater than 
3 to 5 times ULN occurred in 1%, and increases in ALT of more than 5 times ULN occurred in 0.7%. In a study of 
1,538 patients with moderate to severe rheumatoid arthritis, 5.3% and 2.2% of patients developed ALT or AST 
elevations more than 3 times the ULN, respectively. In addition, one patient developed serious drug-induced hepatitis 
with hyperbilirubinemia. Increased frequency and magnitude of transaminase elevations were observed when 
potentially hepatotoxic drugs were used in combination with tocilizumab. For example, among 1,582 patients who 
received 8 mg/kg tocilizumab plus DMARDs, increases in ALT up to 3 times ULN, greater than 3 to 5 times the 
ULN, and greater than 5 times the ULN occurred in 48%, 5%, and 1.5% of patients, respectively. Modification of the 
treatment regimen, such as a reduction in the concomitant DMARD dose, tocilizumab interruption, or tocilizumab 
dose reduction resulted in a decrease or normalization of liver enzymes. Among pediatric patients with PJIA, 4% had 
ALT levels 3 times ULN or greater, and less than 1% had AST levels 3 times ULN or greater. Among patients with 
SJIA, 5% had ALT levels 3 times ULN or greater, and 3% had AST levels greater than 3 times ULN. Over an average 
duration of 73 weeks in the SJIA extension study, ALT levels 3 times ULN or higher were noted in 13%, and AST 
levels 3 times ULN or greater were noted in 5%. Among adult patients with rheumatoid arthritis, increases in ALT 
levels 3 times ULN or greater were noted in 6.5% of weekly subcutaneous tocilizumab recipients and in 3.4% of 
every other week recipients. [38283]
Tocilizumab may cause hyperlipidemia and hypertriglyceridemia, and patient's lipid parameters need to be assessed 
during drug receipt. In clinical trials, lipid parameters were first assessed 6 weeks after tocilizumab initiation. 
Increases in total cholesterol, LDL, HDL, and triglycerides were noted at this time point, but the concentrations 
remained stable with continued tocilizumab receipt. Triglyceride concentrations greater than 500 mg/dL were rarely 
observed. In regard to hypercholesterolemia, the mean LDL increase from baseline to week 24 was 25 mg/dL among 
recipients of tocilizumab 8 mg/kg IV as monotherapy. The mean HDL increase was 4 mg/dL, and the mean 
LDL/HDL ratio increased by 0.26. ApoB/ApoA1 ratios were essentially unchanged, and elevated lipids responded to 
lipid-lowering agents. After SC tocilizumab for rheumatoid arthritis, sustained elevations in total cholesterol more 
than 240 mg/dL were noted in 19% of weekly tocilizumab recipients, in 19.6% of every other week tocilizumab 
recipients, and in 10.2% of placebo recipients. Among patients with systemic juvenile idiopathic arthritis, 1.5% of 
tocilizumab recipients had a total cholesterol concentration more than 1.5 to 2 times the upper limit of normal (ULN) 
as compared with none of the placebo recipients.  Assess lipid parameters approximately 4 to 8 weeks after 
tocilizumab initiation. Subsequently, it is recommended to manage patients according to clinical guidelines [e.g., 
National Cholesterol Educational Program (NCEP)] for the management of hyperlipidemia.[38283]
Tocilizumab may increase the risk of a new primary malignancy. Tocilizumab is an immunosuppressant, and 
treatment with immunosuppressants may result in an increased risk of cancer. Malignancies were observed in clinical 
studies for rheumatoid arthritis, but the impact of tocilizumab receipt on the development of malignancies is not 
known. Over 6 months, 15 malignancies were diagnosed in tocilizumab IV recipients as compared with 8 
malignancies in patients in the control groups. Exposure-adjusted incidence was similar in the tocilizumab groups 
(1.32 events per 100 patient-years) and in the placebo plus DMARD group (1.37 events per 100 patient-years). In the 
all-exposure population, the rate of malignancies remained consistent with the rate observed in the 24-week, 
controlled period.[38283]
Postmarketing reports of anaphylaxis, anaphylactic shock, anaphylactoid reactions (such as angioedema), and death 
have occurred in patients receiving a range of IV tocilizumab doses, with or without concomitant arthritis therapies, 
and in patients who have received premedication. Stevens-Johnson syndrome also has been reported with the 
postmarketing use of IV tocilizumab. In clinical trials, anaphylaxis or hypersensitivity reactions requiring therapy 
discontinuation were generally observed during the second to fourth tocilizumab IV infusion and were reported in 
0.1% of 2,644 patients in the 6-month, controlled trials and in 0.2% of 4,009 patients in the all-exposure population 
for rheumatoid arthritis. As a comparison, hypersensitivity reactions that required treatment discontinuation were 
reported in 0.7% of 1,068 patients in the subcutaneous 6-month controlled trials and in 0.7% of 1,465 patients in the 
subcutaneous all-exposure population for rheumatoid arthritis. For pediatric patients who received IV tocilizumab, 
none of the 188 patients with polyarticular juvenile idiopathic arthritis and 0.9% of 112 patients with systemic 
juvenile idiopathic arthritis had hypersensitivity reactions that required treatment discontinuation. Six of 54 pediatric 
patients with systemic juvenile idiopathic arthritis (SJIA) developed a hypersensitivity reaction during or within 24 
hours of an intravenous tocilizumab infusion; 3 were considered serious and removed from the study. Examples of 
reactions that required treatment discontinuation included generalized erythema, rash, and urticaria. Infusion-related 
reactions defined as events that occurred during or within 24 hours of tocilizumab receipt were noted in 4% to 20.2% 
of patients and consisted of hypertension, headache, nausea, hypotension, dizziness, rash, pruritus, urticaria, diarrhea, 
epigastric discomfort, and arthralgia. In clinical trials of IV tocilizumab for rheumatoid arthritis, rash occurred in 2% 
to 4% of patients, dyspnea or cough in less than 2%, hypertension in 4% to 6%, headache in 5% to 7%, and dizziness 
in 2% to 3%. Consider the diagnosis of hypersensitivity or anaphylaxis in any patient who has an infusion reaction. 
Only administer tocilizumab IV if appropriate medical support to manage anaphylaxis is available. Immediately stop 
the infusion and institute appropriate medical management if an anaphylactic or other serious hypersensitivity 
reaction occurs. For subcutaneous administration, instruct patients to seek immediate medical attention if they 
experience any symptoms of a hypersensitivity reaction. Permanently discontinue tocilizumab if a hypersensitivity 
reaction occurs; tocilizumab is contraindicated for use by patients with known hypersensitivity to the drug. Despite 
prompt medical intervention, a woman died within 24 hours of an anaphylactic event. She experienced 
lightheadedness and hypotension during her fourth tocilizumab infusion, which was stopped after her symptoms 
developed. During her fifth infusion 2 weeks later, she experienced dizziness and hypotension moments after the start 
of the infusion despite premedication with steroids and antihistamines. She became apneic and unresponsive before 
dying. If a hypersensitivity or infusion-related reaction occurs, please report the event to the manufacturer by calling 
1-888-835-2555.[38283] [43101]
A mild to moderate injection site reaction (7.1% to 10%) including erythema, pruritus, pain, and hematoma has been 
noted with subcutaneous tocilizumab administration in adult patients. As a comparison, 2.4% to 4.1% of 
subcutaneous placebo recipients had a local reaction. A higher frequency of injection site reaction (28.8% to 41.2%) 
was observed in pediatric patients receiving subcutaneous tocilizumab. All reactions were mild in severity, but, in the 
polyarticular arthritis group, occurred more commonly in patients weighing 30 kg or more (44%) compared to those 
weighing less than 30 kg (14.8%). The majority of injection site reactions resolved without any treatment, and none 
necessitated drug discontinuation.[38283]
Tocilizumab may increase the risk of macrophage activation syndrome (hemophagocytic lymphohistiocytosis or 
MAS), which is a life-threatening disorder that may develop in patients with rheumatic conditions, especially 
systemic juvenile idiopathic arthritis (SJIA). Limited data from clinical development experience do not suggest that 
tocilizumab increases the incidence of MAS; during clinical trials for SJIA, 3 cases were observed in 112 patients 
who received tocilizumab. Two patients had tocilizumab receipt interrupted, and one patient had tocilizumab 
discontinued for MAS. All three received treatment, and the MAS resolved without sequelae. Of note, infection is a 
trigger for MAS, and tocilizumab is associated with an increased risk of serious infections. Be attentive to symptoms 
of infection or worsening arthritis symptoms; SJIA worsening is also a trigger for macrophage activation syndrome.
[38283] [54707]
Antibody formation against tocilizumab occurred in 46 of 2,876 adult patients with rheumatoid arthritis (1.6%) who 
received IV tocilizumab; 5 of the 46 had an associated, medically significant hypersensitivity reaction that led to 
tocilizumab withdrawal. Thirty adult patients developed neutralizing antibodies to tocilizumab. In polyarticular 
juvenile idiopathic arthritis trials, 1 patient receiving IV tocilizumab and 3 patients receiving subcutaneous 
tocilizumab developed positive antibodies without developing a clinically significant hypersensitivity reaction. Of the 
2 patients in the systemic juvenile idiopathic arthritis (SJIA) trials that developed positive antibodies, one patient 
experienced symptoms associated with an anaphylactic reaction (urticaria and angioedema) and the other developed 
macrophage activation syndrome; both patients discontinued therapy. After subcutaneous drug receipt, 0.9% of 1,454 
adult patients with rheumatoid arthritis developed anti-tocilizumab antibodies, and all but 1 patient also developed 
neutralizing antibodies. The rate is consistent with previous IV experience, and no correlation of antibody 
development to adverse events or loss of clinical response was observed.[38283]
Pancreatitis has been reported with the postmarketing use of tocilizumab.[38283]
Multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in clinical studies of 
tocilizumab. Closely monitor patients for signs and symptoms potentially indicative of demyelinating disorders, such 
as optic neuritis or other visual impairment, peripheral neuropathy (numbness or tingling), or unusual fatigue or 
weakness.[38283]
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Contraindications/Precautions
Absolute contraindications are italicized.
• breast-feeding • children 
• corticosteroid therapy 
• diabetes mellitus 
• diverticulitis 
• fungal infection 
• geriatric 
• GI perforation 
• hepatic disease 
• hepatitis 
• hepatitis B exacerbation 
• hepatotoxicity 
• human immunodeficiency virus (HIV) infection 
• hypercholesterolemia 
• hyperlipidemia 
• hypertriglyceridemia 
• immunosuppression 
• infants 
• infection B
• influenza 
• jaundice 
• labor 
• multiple sclerosis 
• neonates 
• neoplastic disease 
• neurological disease 
• neutropenia 
• new primary malignancy 
• obstetric delivery 
• pregnancy 
• sepsis 
• surgery 
• thrombocytopenia 
• tuberculosis 
• vaccination 
Tocilizumab is contraindicated for use by patients with known hypersensitivity to tocilizumab. Serious 
hypersensitivity reactions, including anaphylaxis, have been reported in association with infusion of tocilizumab. 
Appropriate medical treatment should be available for immediate use in the event of an anaphylactic reaction during 
drug administration.[38283]
Patients who receive tocilizumab are at increased risk for developing serious infections that may lead to 
hospitalization or death. Infections include active tuberculosis and invasive fungal infections including candidiasis, 
aspergillosis, and pneumocystis. Bacterial, viral, and other infections due to opportunistic pathogens have been 
reported. Most patients who developed serious infections were taking concomitant immunosuppressives such as 
methotrexate or corticosteroids. Patients who have surgery while taking tocilizumab may be at greater risk for 
postoperative infections. Patients with an invasive fungal infection may present with disseminated disease, and 
tuberculosis may present as pulmonary or extrapulmonary disease. Evaluate patients for tuberculosis risk factors 
before starting tocilizumab. Also, test patients for latent tuberculosis before and during tocilizumab receipt. Initiate 
treatment for latent infection before tocilizumab use. Consider anti-tuberculosis therapy prior to tocilizumab initiation 
for 2 patient groups: patients with a past history of latent or active tuberculosis in whom an adequate course of 
treatment cannot be confirmed and patients with a negative test for latent tuberculosis but with risk factors for 
tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended 
to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient. Carefully 
consider the risks and benefits of tocilizumab before initiating therapy in patients with chronic or recurrent infection, 
who have been exposed to tuberculosis, with a history of a serious or opportunistic infection, with underlying 
conditions that may predispose them to infection (e.g., patients with advanced or uncontrolled diabetes mellitus, 
human immunodeficiency virus (HIV) infection, or immunosuppression), or who have resided or traveled in areas of 
endemic tuberculosis or endemic mycoses. Tocilizumab initiation is not recommended for patients with an absolute 
neutrophil count (ANC) less than 2,000/mm3, tocilizumab discontinuation is advised for an ANC less than 500/mm3, 
and tocilizumab interruption is advised for an ANC between 500/mm3 and 1000/mm3. Closely monitor patients for 
the development of signs and symptoms of infection during and after tocilizumab treatment; signs and symptoms of 
acute inflammation may be lessened due to suppression of the acute phase reactants. Consider the possible 
development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to taking 
tocilizumab. Do not administer tocilizumab to a patient with an active infection including localized infections. If a 
serious infection such as sepsis or influenza or an opportunistic infection develops, interrupt tocilizumab receipt until 
the infection is controlled. If a new infection develops during tocilizumab receipt, complete a prompt and complete 
diagnostic workup appropriate for an immunocompromised patient, initiate appropriate antimicrobial therapy, and 
closely monitor the patient.
Initiation of tocilizumab is not recommended for thrombocytopenia defined as a platelet count below 100,000 
cells/mm3 or for neutropenia defined as an absolute neutrophil count (ANC) below 2,000 cells/mm3. 
Thrombocytopenia and neutropenia have been noted with tocilizumab, and drug interruption or discontinuation may 
be needed. Check platelet count and ANC before tocilizumab receipt, 4 to 8 weeks after tocilizumab initiation, and 
every 3 months thereafter for adult patients. For pediatric patients with either polyarticular or systemic juvenile 
idiopathic arthritis (JIA), monitor neutrophils and platelets at the time of the second infusion and then every 4 to 8 
weeks for PJIA and every 2 to 4 weeks for SJIA. In patients with severe or life-threatening cytokine release syndrome 
(CRS) who also have cytopenias due to lymphodepleting chemotherapy or the CRS, consider the potential benefit of 
treating the CRS versus the risks of short-term treatment with tocilizumab.[38283]
Use tocilizumab with caution in patients with active hepatic disease or hepatic impairment. Initiation of tocilizumab 
is not recommended in patients who have ALT or AST above 1.5 times the upper limit of normal (ULN). 
Hepatotoxicity, including hepatic injury, hepatic failure, liver transplant, and death have been reported with 
tocilizumab therapy. Following tocilizumab initiation, the time to onset of hepatic injury ranged from months to 
years, and a majority of the patients presented with transaminases levels greater than 5 times the upper limit of 
normal (ULN). However, some patients had mild transaminase elevations along with signs and symptoms of liver 
impairment. Persistent hepatic enzyme elevations during therapy may require dose interruption or consideration of 
drug discontinuation, depending on the clinical abnormality and severity. Check liver function tests before 
tocilizumab receipt, 4 to 8 weeks after the start of therapy for the first 6 months, and then every 3 months after that in 
adult patients. For pediatric patients with either polyarticular or systemic juvenile idiopathic arthritis (JIA), monitor 
liver function tests at the time of the second infusion and then every 4 to 8 weeks for PJIA and every 2 to 4 weeks for 
SJIA. Liver function tests (LFTs) should also be measured in any patient displaying signs and symptoms of liver 
dysfunction, such as fatigue, anorexia, dark urine, jaundice, or right upper abdominal pain. If elevated LFTs are 
detected, then tocilizumab should be stopped and only restarted once liver enzymes have normalized and an 
alternative cause identified. In patients with severe or life-threatening cytokine release syndrome (CRS) who also 
have elevated hepatic enzymes due to lymphodepleting chemotherapy or the CRS, consider the potential benefit of 
treating the CRS versus the risks of short-term treatment with tocilizumab. The safety and efficacy of tocilizumab 
have not been studied in patients with positive hepatitis B virus (HBV) or hepatitis C virus (HCV) serology. 
Tocilizumab may cause HBV or HCV reactivation in patients who are HBV or HCV carriers, which may lead to 
hepatitis C or hepatitis B exacerbation. Consider evaluating patients at risk for HBV and HCV infection for prior 
evidence of infection before tocilizumab initiation. If tocilizumab is initiated in an HBV or HCV carrier, carefully 
monitor the patient for clinical and laboratory signs of active HBV or HCV infection.[38283]
Cautious use of tocilizumab may be warranted by patients with neurological disease such as preexisting or recent 
onset demyelinating disorders. The impact of tocilizumab on demyelinating disorders is not known, but multiple 
sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in clinical studies. Closely 
monitor patients for signs and symptoms potentially indicative of demyelinating disorders.[38283]
Gastrointestinal (GI) perforations and other GI adverse reactions have been reported in clinical studies of tocilizumab. 
GI perforation risk may be increased with concurrent diverticulitis or concomitant use of NSAIDs or corticosteroid 
therapy. Promptly evaluate patients presenting with new onset abdominal symptoms. Cautious tocilizumab use is 
warranted by patients with diverticulitis.[38283]
Tocilizumab is an immunosuppressant and treatment with immunosuppressants may result in an increased risk of 
cancer. The impact of tocilizumab on the development of a new primary malignancy is unknown, but malignancies 
were observed in clinical studies. Consider the risks and benefits of tocilizumab before treatment initiation in patients 
with a history of neoplastic disease. Also, consider the risks and benefits of tocilizumab continuation in patients who 
develop a malignancy.[38283]
Cautious use of tocilizumab may be warranted for patients with hyperlipidemia, hypercholesterolemia, or 
hypertriglyceridemia. Increased total cholesterol, increased HDL-C, increased LDL-C, and increased triglycerides 
may occur with tocilizumab. Assess lipid parameters approximately 4 to 8 weeks after tocilizumab initiation. 
Subsequently, it is recommended to manage patients according to clinical guidelines [e.g., National Cholesterol 
Educational Program (NCEP)] for the management of hyperlipidemia.[38283]
Avoid use of live vaccines concurrently with tocilizumab as clinical safety has not been established. No data are 
available on the secondary transmission of infection from persons receiving live vaccines to patients receiving 
tocilizumab. No data are available on the effectiveness of vaccination in patients receiving tocilizumab. Because IL-6 
inhibition may interfere with the normal immune response to new antigens, it is recommended that all treated 
patients, particularly pediatric patients, if possible, be brought up to date with all immunizations in agreement with 
current immunization guidelines prior to initiating tocilizumab therapy. The interval between live vaccinations and 
initiation of tocilizumab therapy should be in accordance with current vaccination guidelines regarding 
immunosuppressive agents.[38283]
In clinical trials for rheumatoid arthritis, the frequency of serious infections among geriatric patients was higher as 
compared with the frequency among younger adult patients. As there is a higher incidence of infections in the 
geriatric population in general, caution should be used when treating the elderly. Clinical studies that for cytokine 
release syndrome did not include sufficient numbers of patients aged 65 years and older to determine whether they 
respond differently from younger patients.[38283]
Limited available data are not sufficient to determine whether the use of tocilizumab during human pregnancy is 
associated with risk for major birth defects or miscarriage. Based on animal data, there may be a potential risk to the 
fetus. In animal reproduction studies, intravenous administration of tocilizumab to Cynomolgus monkeys during 
organogenesis resulted in abortion/embryo-fetal death at doses 1.25 times or more of the maximum recommended 
human dose (MRHD). Monoclonal antibodies, like tocilizumab, are increasingly transported across the placenta as 
pregnancy progresses, with the largest amount transferred during the third trimester. This may affect the immune 
response in the in utero exposed infant; consider risks and benefits before administering live or live-attenuated 
vaccines to neonates or infants exposed to tocilizumab in utero. A pregnancy registry has been established to monitor 
maternal and fetal outcomes; health care providers are encouraged to register pregnant women exposed to 
tocilizumab by calling 1-877-311-8972.[38283] Due to limited data during pregnancy, guidelines state that tocilizumab 
should be replaced before conception by another medication, if possible. The drug should be used during pregnancy 
only when no other pregnancy-compatible drug can effectively control the maternal disease.[62180] Tocilizumab may 
affect labor and obstetric delivery. Inhibition of IL-6 signaling may interfere with cervical ripening and dilatation and 
myometrial contractile activity, leading to potential delays in parturition.[38283]
The lack of clinical data during lactation precludes clear determination of the risk of tocilizumab to the breast-feeding
infant; therefore the developmental and health benefits of breast-feeding should be considered along with the mother's 
clinical need for tocilizumab and the potential adverse effects on the breastfed child from exposure to the drug or the 
underlying maternal condition. There is no information available on the presence of tocilizumab in human milk or its 
effects on the breast-fed infant or milk production. Maternal immunoglobulin G (IgG) is present in human milk. If 
tocilizumab is transferred into human milk, the effects of local exposure in the gastrointestinal (GI) tract and potential 
limited systemic exposure in the infant to tocilizumab are unknown.[38283] Until more data are available, guidelines 
state that tocilizumab should generally be avoided during breast-feeding if another therapy is available to control the 
maternal disease. The drug has a large molecular weight, and experts suggest the oral bioavailability of any drug 
exposure to the infant through the GI tract is likely low. Breast-feeding should not be discouraged, however, when 
using the drug if no other options are available.[62180]
Tocilizumab is indicated in pediatric patients 2 years of age and older for the treatment of active systemic or 
polyarticular juvenile idiopathic arthritis (JIA) or cytokine release syndrome (CRS). The safety and efficacy of 
tocilizumab in infants and young children less than 2 years of age have not been established. It is recommended that 
all pediatric patients, if possible, be brought up to date with all immunizations in agreement with current 
immunization guidelines prior to initiating tocilizumab therapy. The interval between live vaccinations and initiation 
of tocilizumab therapy should be in accordance with current vaccination guidelines regarding immunosuppressive 
agents.[38283]
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Mechanism of Action
Tocilizumab inhibits IL-6-mediated signaling by competitively binding to both soluble and membrane-bound IL-6 
receptors. IL-6 is a proinflammatory cytokine that is involved in diverse physiological processes such as T-cell 
activation, immunoglobulin secretion induction, hepatic acute-phase protein synthesis initiation, and hematopoietic 
precursor cell proliferation and differentiation stimulation. IL-6 is produced by various cell types, including T- and B-
cells, lymphocytes, monocytes, and fibroblasts. IL-6 is also produced by synovial and endothelial cells leading to 
local production of IL-6 in joints affected by inflammatory processes such as rheumatoid arthritis.[38283]
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Pharmacokinetics
Tocilizumab is administered subcutaneously or intravenously as an infusion. The pharmacokinetics of tocilizumab is 
characterized by nonlinear elimination which is a combination of linear clearance and Michaelis-Menten elimination. 
The nonlinear part of tocilizumab elimination leads to an increase in exposure that is more than dose-proportional. 
The pharmacokinetic parameters of tocilizumab do not change with time. Due to the dependence of total clearance on 
tocilizumab serum concentrations, the half-life of tocilizumab is also concentration-dependent and varies depending 
on the serum concentration level. At higher concentrations, clearance is mainly determined by the linear clearance, 
which was estimated to be 12.5 mL/hour. Linear clearance increases with body size. The concentration-dependent 
nonlinear clearance plays a major role at low concentrations. The half-life of tocilizumab is dependent on the 
concentration.[38283]
A population pharmacokinetic model, based on data in rheumatoid arthritis patients who received either intravenous 
or subcutaneous tocilizumab, found a terminal half-life of approximately 21.5 days at high serum concentrations and 
linear clearance of tocilizumab. Among adult patients with rheumatoid arthritis (RA), the tocilizumab volume of 
distribution (Vd) at steady-state was 6.4 L: the central Vd was 3.5 L, and the peripheral Vd was 2.9 L. For patients 
with rheumatoid arthritis, the concentration-dependent apparent half-life at steady-state is up to 11 days for 4 
mg/kg/dose IV, up to 13 days for 8 mg/kg/dose IV every 4 weeks, up to 13 days for 162 mg subcutaneously every 
week, and 5 days for 162 mg subcutaneously every other week. For adults with giant cell arteritis (GCA) at steady-
state, the effective half-life for 162 mg subcutaneously every week and every other week was 18.3 to 18.9 days and 
4.2 to 7.9 days, respectively.[38283]
Decreases in C-reactive protein to within normal ranges were seen as early as week 2 after tocilizumab 4 mg/kg/dose 
or 8 mg/kg/dose initiation in adults with RA. Decreases in rheumatoid factor, erythrocyte sedimentation rate, serum 
amyloid A, fibrinogen, and increases in hemoglobin were noted with both tocilizumab doses, but the greatest 
improvements were noted with the 8 mg/kg dose. Population pharmacokinetic analyses in any patient population 
tested so far indicate no relationship between apparent clearance and the presence of anti-drug antibodies.[38283]
Affected cytochrome P450 (CYP450) isoenzymes and drug transporters: Unknown, possibly influences CYP enzyme 
activity
In vitro data suggest that IL-6 reduces mRNA expression for several CYP450 isoenzymes including CYP1A2, 
CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and this reduced expression was reversed by coincubation 
with tocilizumab at clinically relevant concentrations. Accordingly, inhibition of IL-6 signaling in patients treated 
with tocilizumab may restore CYP450 activities to higher levels than those in the absence of the drug, leading to 
increased metabolism of drugs that are CYP450 substrates. The drug's effect on CYP2C8 or drug transporters (e.g., P-
glycoprotein) is unknown.[38283]
The restoration of CYP450 enzyme activities may be clinically relevant for CYP450 substrate drugs with a narrow 
therapeutic index (NTI), where the dose is individually adjusted. Upon initiation of tocilizumab, therapeutic 
monitoring of the effect or drug concentration of the NTI drug should be performed; adjust the dose of the NTI drug 
as needed. Caution should be exercised when tocilizumab is coadministered with drugs where a decrease in 
effectiveness is undesirable (e.g., oral contraceptives, which are CYP3A4 substrates). The effect of tocilizumab on 
CYP450 enzyme activity may persist for several weeks after stopping tocilizumab.[38283]
Route-Specific Pharmacokinetics
• Intravenous Route
After receipt of either 4 mg/kg/dose IV or 8 mg/kg/dose IV every 4 weeks, a more than dose-proportional 
increase in systemic exposure and in the trough concentration was noted. At steady-state, the mean 
concentration with 8 mg/kg dosing was 3-fold higher than the systemic exposure after 4 mg/kg dosing. 
The trough concentration at steady-state with 8 mg/kg dosing was 134-fold higher than the trough 
concentration after 4 mg/kg dosing. In contrast, the maximum tocilizumab concentration increased dose-
proportionally. After 4 mg/kg/dose IV every 4 weeks, the estimated median (range) Cmean at steady-state 
was 18 mcg/mL (8.9 to 50.7 mcg/mL), the median (range) steady-state Cmin was 0.1 mcg/mL (0.0 to 14.6 
mcg/mL), and the median (range) steady-state Cmax was 86.1 mcg/mL (44.8 to 202 mcg/mL). Ninety 
percent of steady-state was reached after the first dose for Cmax and AUC and after the fourth dose for 
Cmin. After 8 mg/kg/dose IV every 4 weeks, the median (range) Cmean at steady-state was 54 mcg/mL 
(17 to 260 mcg/mL), the median (range) Cmin at steady-state 13.4 mcg/mL (0.1 to 154 mcg/mL), and 
median (range) Cmax at steady-state was 176 mcg/mL (75.4 to 557 mcg/mL). Approximately 90% of 
steady-state was reached after the first dose for Cmax, after the third dose for AUC, and after the fourth 
dose for Cmin.[38283]
• Subcutaneous Route
After weekly or every other week of 162 mg subcutaneous tocilizumab receipt to patients with rheumatoid 
arthritis (RA), steady-state was achieved after 10 weeks and 12 weeks, respectively. At steady state, the 
estimated median (range) Cmean was 47.3 mcg/mL (2.4 to 147 mcg/mL), Cmin was 42.9 mcg/mL (1.3 to 
144 mcg/mL), and Cmax was 49.8 mcg/mL (3 to 150 mcg/mL) with once-weekly subcutaneous dosing. 
After every other week subcutaneous dosing, the estimated median (range) Cmean was 9.2 mcg/mL (0.2 
to 43.6 mcg/mL), Cmin was 4.1 mcg/mL (0.0 to 34.2 mcg/mL), and Cmax was 12.1 mcg/mL (0.4 to 49.3 
mcg/mL) at steady-state. Systemic exposures with once-weekly dosing were 5.1-fold higher for Cmean 
and 10.5-fold higher for Cmin compared to every other week dosing. Accumulation for Cmin was greater 
following subcutaneous, both once weekly and every other week regimens, compared to intravenous 
administration and is expected based on the non-linear clearance at lower concentrations. Greater than 
90% of the steady-state value for Cmax was achieved after the fifth dose with the once-weekly regimen 
and 12th dose with every other week regimen. Ninety percent of the steady-state values for the Cmean and 
Cmin were achieved after the 6th and 12th injections, for the every other week and once-weekly regimens, 
respectively.[38283]
In patients, at steady-state, with giant cell arteritis (GCA) who received 162 mg tocilizumab 
subcutaneously every week, the estimated median (range) Cmax was 72.1 mcg/mL (12.2 to 151 mcg/mL), 
Cmin was 67.2 mcg/mL (10.7 to 145 mcg/mL), and Cmean was 70.6 mcg/mL (11.7 to 149 mcg/mL). For 
patients at steady-state who received 162 mg every other week, the estimated median (range) Cmax, 
Cmin, and Cmean were 17.2 mcg/mL (1.1 to 56.2 mcg/mL), 7.7 mcg/mL (0.1 to 37.3 mcg/mL), and 13.7 
mcg/mL (0.5 to 49 mcg/mL), respectively. Steady-state was reached at 17 weeks and 14 weeks following 
once weekly and every other week dosing regimens, respectively.[38283]
Special Populations
• Hepatic Impairment
No formal study of the effect of hepatic impairment on the pharmacokinetics of tocilizumab was 
conducted; treatment with tocilizumab is not recommended in patients with active hepatic disease or 
hepatic impairment.[38283]
• Renal Impairment
Mild to moderate renal impairment defined as a CrCl 30 to 79 mL/minute did not impact the 
pharmacokinetic parameters of tocilizumab during clinical trials for various indications; no dosage 
adjustments are needed for patients with mild to moderate renal impairment.[38283]
• Pediatrics
Children and Adolescents 2 to 17 years
Polyarticular juvenile idiopathic arthritis (PJIA)
In pediatric patients with PJIA, the central volume of distribution (Vd) of tocilizumab is 1.98 L, and the 
peripheral Vd is 2.1 L, resulting in a steady-state Vd of 4.08 L. Linear clearance is 5.8 mL/hour. Half-life 
is up to 17 days for IV administration or 10 days for subcutaneous administration.[38283]
Average and trough concentrations of tocilizumab at steady-state in pediatric patients (dose = 8 
mg/kg/dose or 10 mg/kg/dose IV every 4 weeks) are comparable to those observed in adult rheumatoid 
arthritis (RA) patients receiving 4 mg/kg/dose or 8 mg/kg/dose IV every 4 weeks and peak concentration 
similar to adult dose of 8 mg/kg/dose IV every 4 weeks in adult RA patients. The average concentration 
(Cmean) of tocilizumab in PJIA patients is slightly lower compared than that observed in adult RA 
patients. For doses of 8 mg/kg/dose IV every 4 weeks (patients weighing 30 kg or more), estimated 
median Cmax, Cmin, and Cmean were 181 mcg/mL, 3.28 mcg/mL, and 38.6 mcg/mL, respectively, during 
pharmacokinetic trials. For doses of 10 mg/kg/dose IV every 4 weeks (patients weighing less than 30 kg), 
estimated median Cmax, Cmin, and Cmean were 167 mcg/mL, 0.35 mcg/mL, and 30.8 mcg/mL, 
respectively.[38283]
Bioavailability for subcutaneous tocilizumab in PJIA patients is 96%, and the absorption half-life is 
around 2 days. Average trough concentrations in pediatric patients after subcutaneous dosing are within 
the range of those achieved in adult patients with RA. Patients treated with subcutaneous tocilizumab have 
a steady-state Cmin at or higher than that achieved with IV administration. In general, steady-state Cmin is 
comparable in patients in both body weight groups (less than 30 kg and 30 kg or more), while steady-state 
Cmax and Cmean are higher for patients in the lower weight group. For doses of 162 mg subcutaneous 
every 2 weeks (patients weighing 30 kg or more), estimated median Cmax, Cmin, and Cmean were 29.7 
mcg/mL, 12.7 mcg/mL, and 23 mcg/mL, respectively, during pharmacokinetic trials. For doses of 162 mg 
subcutaneous every 3 weeks (patients weighing less than 30 kg), estimated median Cmax, Cmin, and 
Cmean were 62.4 mcg/mL, 13.4 mcg/mL, and 35.7 mcg/mL, respectively.[38283]
Systemic juvenile idiopathic arthritis (SJIA)
In pediatric patients with SJIA, the central Vd of tocilizumab is 1.87 L, and the peripheral Vd is 2.14 L, 
resulting in a steady-state Vd of 4.01 L. Linear clearance is 5.7 mL/hour. Half-life is up to 16 days for IV 
administration or 14 days for subcutaneous administration.[38283]
For doses of 8 mg/kg/dose IV every 2 weeks (patients weighing 30 kg or more), estimated median Cmax, 
Cmin, and Cmean were 253 mcg/mL, 70.7 mcg/mL, and 117 mcg/mL, respectively, during 
pharmacokinetic trials. For doses of 12 mg/kg/dose IV every 2 weeks (patients weighing less than 30 kg), 
estimated median Cmax, Cmin, and Cmean were 274 mcg/mL, 65.9 mcg/mL, and 124 mcg/mL, 
respectively. Steady-state was reached by 8 weeks for both groups. Mean estimated tocilizumab exposure 
parameters were similar between the 2 dose groups defined by body weight.[38283]
Bioavailability for subcutaneous tocilizumab in SJIA patients is 95%, and absorption half-life is around 2 
days. Patients treated with subcutaneous tocilizumab have a steady-state Cmax lower than that achieved 
with IV administration. Steady-state Cmin and Cmean are comparable in patients after subcutaneous or IV 
dosing across body weights. For doses of 162 mg subcutaneous every week (patients weighing 30 kg or 
more), estimated median Cmax, Cmin, and Cmean were 89.8 mcg/mL, 72.4 mcg/mL, and 82.4 mcg/mL, 
respectively, during pharmacokinetic trials. For doses of 162 mg subcutaneous every 2 weeks (patients 
weighing less than 30 kg), estimated median Cmax, Cmin, and Cmean were 127 mcg/mL, 64.2 mcg/mL, 
and 92.7 mcg/mL, respectively. Steady-state was reached by 12 weeks for both groups.[38283]
• Geriatric
Age was not shown to have an effect on the pharmacokinetics of tocilizumab.[38283]
• Gender Differences
Gender was not shown to have an effect on the pharmacokinetics of tocilizumab.[38283]
• Ethnic Differences
Race was not shown to have an effect on the pharmacokinetics of tocilizumab.[38283]
• Obesity
Population analysis identified body weight as a significant covariate impacting the pharmacokinetics of 
tocilizumab. When given IV on a mg/kg basis, individuals weighing 100 kg or more are predicted to have 
mean steady-state exposures higher than mean values for the patient population. In RA patients, the body 
weight-based dose (8 mg per kg) resulted in approximately 86% higher exposure in patients weighing 
more than 100 kg in comparison to patients who weigh less than 60 kg. Therefore, tocilizumab doses 
exceeding 800 mg per IV infusion are not recommended in patients with RA. There was an inverse 
relationship between tocilizumab exposure and body weight for flat dose subcutaneous regimens. Due to 
the flat dosing employed for subcutaneous administration of tocilizumab, no modifications are necessary 
by this dosing route.[38283]
In GCA patients, higher exposure was observed in patients with lower body weight. For the 162 mg every 
week dosing regimen, the steady-state Cmean was 51% higher in patients with body weight less than 60 
kg compared to patients weighing between 60 to 100 kg. For the 162 mg every other week regimen, the 
steady-state Cmean was 129% higher in patients weighing less than 60 kg compared to patients weighing 
between 60 to 100 kg. There is limited data for patients above 100 kg (n=7). Due to the flat dosing 
employed for subcutaneous administration of tocilizumab, no modifications are necessary by this dosing 
route.[38283]
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Pregnancy/Breast-feeding
Pregnancy
Limited available data are not sufficient to determine whether the use of tocilizumab during human pregnancy is 
associated with risk for major birth defects or miscarriage. Based on animal data, there may be a potential risk to the 
fetus. In animal reproduction studies, intravenous administration of tocilizumab to Cynomolgus monkeys during 
organogenesis resulted in abortion/embryo-fetal death at doses 1.25 times or more of the maximum recommended 
human dose (MRHD). Monoclonal antibodies, like tocilizumab, are increasingly transported across the placenta as 
pregnancy progresses, with the largest amount transferred during the third trimester. This may affect the immune 
response in the in utero exposed infant; consider risks and benefits before administering live or live-attenuated 
vaccines to neonates or infants exposed to tocilizumab in utero. A pregnancy registry has been established to monitor 
maternal and fetal outcomes; health care providers are encouraged to register pregnant women exposed to 
tocilizumab by calling 1-877-311-8972.[38283] Due to limited data during pregnancy, guidelines state that tocilizumab 
should be replaced before conception by another medication, if possible. The drug should be used during pregnancy 
only when no other pregnancy-compatible drug can effectively control the maternal disease.[62180] Tocilizumab may 
affect labor and obstetric delivery. Inhibition of IL-6 signaling may interfere with cervical ripening and dilatation and 
myometrial contractile activity, leading to potential delays in parturition.[38283]
Breast-Feeding
The lack of clinical data during lactation precludes clear determination of the risk of tocilizumab to the breast-feeding 
infant; therefore the developmental and health benefits of breast-feeding should be considered along with the mother's 
clinical need for tocilizumab and the potential adverse effects on the breastfed child from exposure to the drug or the 
underlying maternal condition. There is no information available on the presence of tocilizumab in human milk or its 
effects on the breast-fed infant or milk production. Maternal immunoglobulin G (IgG) is present in human milk. If 
tocilizumab is transferred into human milk, the effects of local exposure in the gastrointestinal (GI) tract and potential 
limited systemic exposure in the infant to tocilizumab are unknown.[38283] Until more data are available, guidelines 
state that tocilizumab should generally be avoided during breast-feeding if another therapy is available to control the 
maternal disease. The drug has a large molecular weight, and experts suggest the oral bioavailability of any drug 
exposure to the infant through the GI tract is likely low. Breast-feeding should not be discouraged, however, when 
using the drug if no other options are available.[62180]
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Interactions
Level 2 (Major)
• Abatacept
• Anakinra
• Bacillus Calmette-Guerin Vaccine, BCG
• Baricitinib
• Basiliximab
• Canakinumab
• Daclizumab
• Efalizumab
• Influenza Virus Vaccine
• Intranasal Influenza Vaccine
• Live Vaccines
• Measles Virus; Mumps Virus; Rubella Virus; 
Varicella Virus Vaccine, Live
• Measles/Mumps/Rubella Vaccines, MMR
• Muromonab-CD3
• Ofatumumab
• Rituximab
• Rituximab; Hyaluronidase
• Rotavirus Vaccine
• Rubella Virus Vaccine Live
• Sarilumab
• Secukinumab
• Smallpox and Monkeypox Vaccine, Live, 
Nonreplicating
• Smallpox Vaccine, Vaccinia Vaccine
• Tofacitinib
• Tumor Necrosis Factor modifiers
• Typhoid Vaccine
• Upadacitinib
• Ustekinumab
• Varicella-Zoster Virus Vaccine, Live
• Yellow Fever Vaccine, Live
Level 3 (Moderate)
• Alfentanil
• Amlodipine; Atorvastatin
• Apixaban
• Atorvastatin
• Atorvastatin; Ezetimibe
• Belladonna Alkaloids; Ergotamine; Phenobarbital
• Caffeine; Ergotamine
• Carbamazepine
• Cisapride
• Cyclosporine
• Dextromethorphan; Quinidine
• Dihydroergotamine
• Ergotamine
• Ethosuximide
• Everolimus
• Ezetimibe; Simvastatin
• Fentanyl
• Fosphenytoin
• Hydrocortisone
• Lovastatin
• Lovastatin; Niacin
• Niacin; Simvastatin
• Oral Contraceptives
• Phenytoin
• Pimozide
• Quinidine
• Rivaroxaban
• Simvastatin
• Simvastatin; Sitagliptin
• Sirolimus
• Tacrolimus
• Theophylline, Aminophylline
• Thioridazine
• Tizanidine
• Warfarin
Level 4 (Minor)
• Acetaminophen; Chlorpheniramine; 
Dextromethorphan; Phenylephrine
• Acetaminophen; Chlorpheniramine; 
Dextromethorphan; Pseudoephedrine
• Acetaminophen; Dextromethorphan
• Acetaminophen; Dextromethorphan; Doxylamine
• Acetaminophen; Dextromethorphan; Guaifenesin; 
Phenylephrine
• Acetaminophen; Dextromethorphan; 
Phenylephrine
• Acetaminophen; Dextromethorphan; 
Pseudoephedrine
• Amoxicillin; Clarithromycin; Omeprazole
• Aspirin, ASA; Omeprazole
• Brompheniramine; Dextromethorphan; 
Guaifenesin
• Carbinoxamine; Dextromethorphan; 
Pseudoephedrine
• Chlorpheniramine; Dextromethorphan
• Chlorpheniramine; Dextromethorphan; 
Phenylephrine
• Dexchlorpheniramine; Dextromethorphan; 
Pseudoephedrine
• Dextromethorphan
• Dextromethorphan; Diphenhydramine; 
Phenylephrine
• Dextromethorphan; Guaifenesin
• Dextromethorphan; Guaifenesin; Phenylephrine
• Dextromethorphan; Guaifenesin; Potassium 
Guaiacolsulfonate
• Dextromethorphan; Guaifenesin; 
Pseudoephedrine
• Dextromethorphan; Promethazine
• Omeprazole
• Omeprazole; Amoxicillin; Rifabutin
• Omeprazole; Sodium Bicarbonate
Abatacept: (Major) Avoid the concomitant use of tocilizumab with biological DMARDs, including selective 
costimulation modulators such as abatacept; coadministration has not been studied and may result in additive 
immunosuppression and increased risk of infection. [27940] [38283]
Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine: (Minor) Concomitant use of tocilizumab and 
dextromethorphan may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction 
is not known or established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% 
decrease in dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a 
single tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 
substrate. [38283] [42280] [56579]
Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine: (Minor) Concomitant use of tocilizumab 
and dextromethorphan may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this 
interaction is not known or established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to 
higher levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior 
to treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% 
decrease in dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a 
single tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 
substrate. [38283] [42280] [56579]
Acetaminophen; Dextromethorphan: (Minor) Concomitant use of tocilizumab and dextromethorphan may lead to a 
decrease in the efficacy of dextromethorphan; clinical significance of this interaction is not known or established. 
Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect on 
CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% decrease in 
dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a single 
tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 substrate. [38283]
[42280] [56579]
Acetaminophen; Dextromethorphan; Doxylamine: (Minor) Concomitant use of tocilizumab and dextromethorphan 
may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction is not known or 
established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% decrease in 
dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a single 
tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 substrate. [38283]
[42280] [56579]
Acetaminophen; Dextromethorphan; Guaifenesin; Phenylephrine: (Minor) Concomitant use of tocilizumab and 
dextromethorphan may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction 
is not known or established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% 
decrease in dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a 
single tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 
substrate. [38283] [42280] [56579]
Acetaminophen; Dextromethorphan; Phenylephrine: (Minor) Concomitant use of tocilizumab and dextromethorphan 
may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction is not known or 
established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% decrease in 
dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a single 
tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 substrate. [38283]
[42280] [56579]
Acetaminophen; Dextromethorphan; Pseudoephedrine: (Minor) Concomitant use of tocilizumab and 
dextromethorphan may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction 
is not known or established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% 
decrease in dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a 
single tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 
substrate. [38283] [42280] [56579]
Alfentanil: (Moderate) Monitor for evidence of reduced effect if alfentanil coadministration with tocilizumab is 
necessary; alfentanil dosage adjustment may be needed. Inhibition of IL-6 signaling by tocilizumab may restore 
CYP450 activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to 
metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as alfentanil, may 
have fluctuations in drug levels and therapeutic effect when tocilizumab therapy is started or discontinued. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the 
potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Alfentanil is a CYP3A4 substrate and narrow therapeutic index drug. [38283]
Amlodipine; Atorvastatin: (Moderate) Utilize caution with concomitant use of tocilizumab and CYP3A4 substrate 
drugs, such as atorvastatin, where a decrease in effectiveness is undesirable. Monitor lipid panels and adjust therapy 
as indicated. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 57% decrease in the 
exposure of another "statin" was noted 1 week after a single tocilizumab dose. In vitro, tocilizumab has the potential 
to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Atorvastatin is a CYP3A4 substrate. [38283]
Amoxicillin; Clarithromycin; Omeprazole: (Minor) Concomitant use of tocilizumab and omeprazole may lead to a 
decrease in the efficacy of omeprazole. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to 
higher levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior 
to treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 12 
to 28% decrease in omeprazole exposure occurred 1 week after a single tocilizumab dose. In vitro, tocilizumab has 
the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Omeprazole is a substrate of both CYP2C19 and CYP3A4. [38283]
Anakinra: (Major) Avoid the concomitant use of tocilizumab with biological DMARDs, including interleukin-1 
receptor antagonists such as anakinra; coadministration has not been studied and may result in additive 
immunosuppression and increased risk of infection. [27940] [38283]
Apixaban: (Moderate) Monitor for a decrease in efficacy of apixaban if used with tocilizumab. Until more data are 
available, consider using an anticoagulant without dependence on CYP450 enzymes for metabolism (e.g., heparins, 
edoxaban). The formation of CYP450 enzymes may be suppressed by increased concentrations of cytokines such as 
IL-6 during chronic inflammation. It is expected that the activity of CYP450 enzymes could increase to normal 
concentrations during treatment with an IL-6 antagonist such as tocilizumab; these effects on CYP450 enzyme 
activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to affect 
expression of multiple CYP enzymes [including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4]. 
Apixaban is a substrate for CYP3A4. [38283] [52739] [65210]
Aspirin, ASA; Omeprazole: (Minor) Concomitant use of tocilizumab and omeprazole may lead to a decrease in the 
efficacy of omeprazole. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels 
leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. 
This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 12 to 28% 
decrease in omeprazole exposure occurred 1 week after a single tocilizumab dose. In vitro, tocilizumab has the 
potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Omeprazole is a substrate of both CYP2C19 and CYP3A4. [38283]
Atorvastatin: (Moderate) Utilize caution with concomitant use of tocilizumab and CYP3A4 substrate drugs, such as 
atorvastatin, where a decrease in effectiveness is undesirable. Monitor lipid panels and adjust therapy as indicated. 
Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect on 
CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 57% decrease in the exposure of 
another "statin" was noted 1 week after a single tocilizumab dose. In vitro, tocilizumab has the potential to affect 
expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 
Atorvastatin is a CYP3A4 substrate. [38283]
Atorvastatin; Ezetimibe: (Moderate) Utilize caution with concomitant use of tocilizumab and CYP3A4 substrate 
drugs, such as atorvastatin, where a decrease in effectiveness is undesirable. Monitor lipid panels and adjust therapy 
as indicated. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 57% decrease in the 
exposure of another "statin" was noted 1 week after a single tocilizumab dose. In vitro, tocilizumab has the potential 
to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Atorvastatin is a CYP3A4 substrate. [38283]
Bacillus Calmette-Guerin Vaccine, BCG: (Major) Avoid concurrent use of live vaccines during treatment with 
tocilizumab due to potentially increased risk of infections; clinical safety of live vaccines during tocilizumab 
treatment has not been established. No data are available on the secondary transmission of infection from persons 
receiving live vaccines to patients receiving tocilizumab. The interval between live vaccinations and initiation of 
tocilizumab therapy should be in accordance with current vaccination guidelines regarding immunosuppressive 
agents. [38283] [51778]
Baricitinib: (Major) Avoid the concomitant use of tocilizumab with other biological DMARDs such as baricitinib; 
coadministration has not been studied and may result in additive immunosuppression and increased risk of infection. 
[38283] [63229]
Basiliximab: (Major) Avoid using tocilizumab with immunosuppressive biological agents such as basilixumab 
because of the possibility of increased immunosuppression and increased risk of infection. The concurrent use of 
tocilizumab with other biological agents has not been studied. Most patients taking tocilizumab who developed 
serious infections were taking concomitant immunosuppressives. [28018] [38283]
Belladonna Alkaloids; Ergotamine; Phenobarbital: (Moderate) Monitor for decreased efficacy of ergotamine if 
coadministration with tocilizumab is necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 
activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to 
metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as ergotamine, 
may have fluctuations in drug levels and therapeutic effect when tocilizumab therapy is started or discontinued. This 
effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has 
the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Ergotamine is a CYP3A4 substrate and narrow therapeutic index drug. [38283]
Brompheniramine; Dextromethorphan; Guaifenesin: (Minor) Concomitant use of tocilizumab and dextromethorphan 
may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction is not known or 
established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% decrease in 
dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a single 
tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 substrate. [38283]
[42280] [56579]
Caffeine; Ergotamine: (Moderate) Monitor for decreased efficacy of ergotamine if coadministration with tocilizumab 
is necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment. Therefore, 
CYP450 substrates with a narrow therapeutic index, such as ergotamine, may have fluctuations in drug levels and 
therapeutic effect when tocilizumab therapy is started or discontinued. This effect on CYP450 enzyme activity may 
persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Ergotamine is a 
CYP3A4 substrate and narrow therapeutic index drug. [38283]
Canakinumab: (Major) Avoid using tocilizumab with other biological DMARDs including interleukin-1 receptor 
antagonists such as canakinumab; coadministration has not been studied and may result in additive 
immunosuppression and increased risk of infection. [38283]
Carbamazepine: (Moderate) Monitor carbamazepine concentrations and watch for decreased efficacy of 
carbamazepine if coadministration with tocilizumab is necessary; adjust carbamazepine dosage as necessary. 
Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 
substrates with a narrow therapeutic index, such as carbamazepine, may have fluctuations in drug levels and 
therapeutic effect when tocilizumab therapy is started or discontinued. This effect on CYP450 enzyme activity may 
persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Carbamazepine 
is a substrate of both CYP1A2 and CYP3A4 and narrow therapeutic index drug. [38283]
Carbinoxamine; Dextromethorphan; Pseudoephedrine: (Minor) Concomitant use of tocilizumab and 
dextromethorphan may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction 
is not known or established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% 
decrease in dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a 
single tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 
substrate. [38283] [42280] [56579]
Chlorpheniramine; Dextromethorphan: (Minor) Concomitant use of tocilizumab and dextromethorphan may lead to a 
decrease in the efficacy of dextromethorphan; clinical significance of this interaction is not known or established. 
Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect on 
CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% decrease in 
dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a single 
tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 substrate. [38283]
[42280] [56579]
Chlorpheniramine; Dextromethorphan; Phenylephrine: (Minor) Concomitant use of tocilizumab and 
dextromethorphan may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction 
is not known or established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% 
decrease in dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a 
single tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 
substrate. [38283] [42280] [56579]
Cisapride: (Moderate) Monitor for decreased efficacy of cisapride if coadministration with tocilizumab is necessary. 
Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 
substrates with a narrow therapeutic index, such as cisapride, may have fluctuations in drug levels and therapeutic 
effect when tocilizumab therapy is started or discontinued. This effect on CYP450 enzyme activity may persist for 
several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to affect expression of multiple CYP 
enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Cisapride is a CYP3A4 
substrate and narrow therapeutic index drug. [38283]
Cyclosporine: (Moderate) Monitor cyclosporine levels and adjust the dose of cyclosporine as appropriate if 
coadministration with tocilizumab is necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 
activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to 
metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as cyclosporine, 
may have fluctuations in drug levels and therapeutic effect when tocilizumab therapy is started or discontinued. This 
effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has 
the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Cyclosporine is a CYP3A4 substrate and narrow therapeutic index drug. [38283]
Daclizumab: (Major) Avoid using tocilizumab with biological immunosuppressive agents because of the possibility 
of increased immunosuppression and increased risk of infection. The concurrent use of tocilizumab with biological 
DMARDs such as daclizumab has not been studied. Daclizumab is a biologic monoclonal antibody binds specifically 
to the alpha subunit of the human high-affinity interleukin (IL)-2 receptor, producing immunosuppression. [38283]
[60841]
Dexchlorpheniramine; Dextromethorphan; Pseudoephedrine: (Minor) Concomitant use of tocilizumab and 
dextromethorphan may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction 
is not known or established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% 
decrease in dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a 
single tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 
substrate. [38283] [42280] [56579]
Dextromethorphan: (Minor) Concomitant use of tocilizumab and dextromethorphan may lead to a decrease in the 
efficacy of dextromethorphan; clinical significance of this interaction is not known or established. Inhibition of IL-6 
signaling by tocilizumab may restore CYP450 activities to higher levels leading to increased metabolism of drugs that 
are CYP450 substrates as compared to metabolism prior to treatment. This effect on CYP450 enzyme activity may 
persist for several weeks after stopping tocilizumab. A 5% decrease in dextromethorphan exposure and a 29% 
decrease in its metabolite, dextrorphan was noted 1 week after a single tocilizumab infusion. In vitro, tocilizumab has 
the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 substrate. [38283] [42280] [56579]
Dextromethorphan; Diphenhydramine; Phenylephrine: (Minor) Concomitant use of tocilizumab and 
dextromethorphan may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction 
is not known or established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% 
decrease in dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a 
single tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 
substrate. [38283] [42280] [56579]
Dextromethorphan; Guaifenesin: (Minor) Concomitant use of tocilizumab and dextromethorphan may lead to a 
decrease in the efficacy of dextromethorphan; clinical significance of this interaction is not known or established. 
Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect on 
CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% decrease in 
dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a single 
tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 substrate. [38283]
[42280] [56579]
Dextromethorphan; Guaifenesin; Phenylephrine: (Minor) Concomitant use of tocilizumab and dextromethorphan may 
lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction is not known or 
established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% decrease in 
dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a single 
tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 substrate. [38283]
[42280] [56579]
Dextromethorphan; Guaifenesin; Potassium Guaiacolsulfonate: (Minor) Concomitant use of tocilizumab and 
dextromethorphan may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction 
is not known or established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% 
decrease in dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a 
single tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 
substrate. [38283] [42280] [56579]
Dextromethorphan; Guaifenesin; Pseudoephedrine: (Minor) Concomitant use of tocilizumab and dextromethorphan 
may lead to a decrease in the efficacy of dextromethorphan; clinical significance of this interaction is not known or 
established. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% decrease in 
dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a single 
tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 substrate. [38283]
[42280] [56579]
Dextromethorphan; Promethazine: (Minor) Concomitant use of tocilizumab and dextromethorphan may lead to a 
decrease in the efficacy of dextromethorphan; clinical significance of this interaction is not known or established. 
Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect on 
CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 5% decrease in 
dextromethorphan exposure and a 29% decrease in its metabolite, dextrorphan was noted 1 week after a single 
tocilizumab infusion. In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dextromethorphan is a CYP2D6 substrate. [38283]
[42280] [56579]
Dextromethorphan; Quinidine: (Moderate) Monitor quinidine levels and adjust the dose of quinidine as appropriate if 
coadministration with tocilizumab is necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 
activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to 
metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as quinidine, may 
have fluctuations in drug levels and therapeutic effect when tocilizumab therapy is started or discontinued. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the 
potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Quinidine is a CYP3A4 substrate and narrow therapeutic index drug. [38283] (Minor) 
Concomitant use of tocilizumab and dextromethorphan may lead to a decrease in the efficacy of dextromethorphan; 
clinical significance of this interaction is not known or established. Inhibition of IL-6 signaling by tocilizumab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates as 
compared to metabolism prior to treatment. This effect on CYP450 enzyme activity may persist for several weeks 
after stopping tocilizumab. A 5% decrease in dextromethorphan exposure and a 29% decrease in its metabolite, 
dextrorphan was noted 1 week after a single tocilizumab infusion. In vitro, tocilizumab has the potential to affect 
expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 
Dextromethorphan is a CYP2D6 substrate. [38283] [42280] [56579]
Dihydroergotamine: (Moderate) Monitor for decreased efficacy of dihydroergotamine if coadministration with 
tocilizumab is necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels 
leading to increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment. 
Therefore, CYP450 substrates with a narrow therapeutic index, such as dihydroergotamine, may have fluctuations in 
drug levels and therapeutic effect when tocilizumab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to 
affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Dihydroergotamine is a CYP3A4 substrate and narrow therapeutic index drug. [38283]
Efalizumab: (Major) Avoid using tocilizumab with other biological DMARDs because of the possibility of increased 
immunosuppression and increased risk of infection. The concurrent use of tocilizumab with biological DMARDs 
such as efalizumab has not been studied. [38283] [59721]
Ergotamine: (Moderate) Monitor for decreased efficacy of ergotamine if coadministration with tocilizumab is 
necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment. Therefore, 
CYP450 substrates with a narrow therapeutic index, such as ergotamine, may have fluctuations in drug levels and 
therapeutic effect when tocilizumab therapy is started or discontinued. This effect on CYP450 enzyme activity may 
persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Ergotamine is a 
CYP3A4 substrate and narrow therapeutic index drug. [38283]
Ethosuximide: (Moderate) Monitor for reduced efficacy of ethosuximide, monitor drug concentrations, and adjust the 
dose of ethosuximide as appropriate if coadministration with tocilizumab is necessary. Inhibition of IL-6 signaling by 
tocilizumab may restore CYP450 activities to higher levels leading to increased metabolism of drugs that are CYP450 
substrates compared to metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, 
such as ethosuximide, may have fluctuations in drug levels and therapeutic effect when tocilizumab therapy is started 
or discontinued. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. In 
vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Ethosuximide is a CYP3A4 substrate and narrow therapeutic index 
drug. [38283]
Everolimus: (Moderate) Monitor for clinical response in patients taking everolimus concurrently with tocilizumab. 
For indications where therapeutic drug monitoring is appropriate, monitor everolimus trough concentrations and 
adjust the dose of everolimus accordingly. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities 
to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to metabolism prior 
to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as everolimus, may have 
fluctuations in drug levels and therapeutic effect when tocilizumab therapy is started or discontinued. This effect on 
CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the 
potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Everolimus is a CYP3A4 substrate and narrow therapeutic index drug. [38283]
Ezetimibe; Simvastatin: (Moderate) Utilize caution with concomitant use of tocilizumab and CYP3A4 substrate 
drugs, such as simvastatin, where a decrease in effectiveness is undesirable. Monitor lipid panels and adjust therapy 
as indicated. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 57% decrease in simvastatin 
exposure was noted 1 week after a single tocilizumab dose. In vitro, tocilizumab has the potential to affect expression 
of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Simvastatin 
is a CYP3A4 substrate. [38283]
Fentanyl: (Moderate) Monitor for evidence of reduced pain control or opioid withdrawal if fentanyl coadministration 
with tocilizumab is necessary; fentanyl dosage adjustment may be needed. Inhibition of IL-6 signaling by sarilumab 
may restore CYP450 activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates 
compared to metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as 
fentanyl, may have fluctuations in drug levels and therapeutic effect when sarilumab therapy is started or 
discontinued. This effect on CYP450 enzyme activity may persist for several weeks after stopping sarilumab. In vitro, 
sarilumab has the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A4. Fentanyl is a CYP3A4 substrate and narrow therapeutic index drug. [38283]
Fosphenytoin: (Moderate) Monitor drug concentrations and watch for decreased efficacy of fosphenytoin if use with 
tocilizumab is necessary; adjust fosphenytoin dosage as necessary. Inhibition of IL-6 signaling by tocilizumab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates 
compared to metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as 
fosphenytoin, may have fluctuations in drug levels and therapeutic effect when tocilizumab therapy is started or 
discontinued. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. In 
vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Fosphenytoin is a substrate of both CYP2C9 and CYP2C19 and 
narrow therapeutic index drug. [38283]
Hydrocortisone: (Moderate) Closely observe patients for signs of infection. Most patients taking tocilizumab who 
developed serious infections were taking concomitant immunosuppressives such as systemic corticosteroids. [38283]
Influenza Virus Vaccine: (Major) Avoid concurrent use of live vaccines during treatment with tocilizumab due to 
potentially increased risk of infections; clinical safety of live vaccines during tocilizumab treatment has not been 
established. No data are available on the secondary transmission of infection from persons receiving live vaccines to 
patients receiving tocilizumab. The interval between live vaccinations and initiation of tocilizumab therapy should be 
in accordance with current vaccination guidelines regarding immunosuppressive agents. [38283] [51778]
Intranasal Influenza Vaccine: (Major) Avoid concurrent use of live vaccines during treatment with tocilizumab due to 
potentially increased risk of infections; clinical safety of live vaccines during tocilizumab treatment has not been 
established. No data are available on the secondary transmission of infection from persons receiving live vaccines to 
patients receiving tocilizumab. The interval between live vaccinations and initiation of tocilizumab therapy should be 
in accordance with current vaccination guidelines regarding immunosuppressive agents. [38283] [51778]
Live Vaccines: (Major) Avoid concurrent use of live vaccines during treatment with tocilizumab due to potentially 
increased risk of infections; clinical safety of live vaccines during tocilizumab treatment has not been established. No 
data are available on the secondary transmission of infection from persons receiving live vaccines to patients 
receiving tocilizumab. The interval between live vaccinations and initiation of tocilizumab therapy should be in 
accordance with current vaccination guidelines regarding immunosuppressive agents. [38283] [51778]
Lovastatin: (Moderate) Utilize caution with concomitant use of tocilizumab and CYP3A4 substrate drugs, such as 
lovastatin, where a decrease in effectiveness is undesirable. Monitor lipid panels and adjust therapy as indicated. 
Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect on 
CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 57% decrease in the exposure of 
another "statin" was noted 1 week after a single tocilizumab dose. In vitro, tocilizumab has the potential to affect 
expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 
Lovastatin is a CYP3A4 substrate. [38283]
Lovastatin; Niacin: (Moderate) Utilize caution with concomitant use of tocilizumab and CYP3A4 substrate drugs, 
such as lovastatin, where a decrease in effectiveness is undesirable. Monitor lipid panels and adjust therapy as 
indicated. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 57% decrease in the 
exposure of another "statin" was noted 1 week after a single tocilizumab dose. In vitro, tocilizumab has the potential 
to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Lovastatin is a CYP3A4 substrate. [38283]
Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live: (Major) Avoid concurrent use of live 
vaccines during treatment with tocilizumab due to potentially increased risk of infections; clinical safety of live 
vaccines during tocilizumab treatment has not been established. No data are available on the secondary transmission 
of infection from persons receiving live vaccines to patients receiving tocilizumab. The interval between live 
vaccinations and initiation of tocilizumab therapy should be in accordance with current vaccination guidelines 
regarding immunosuppressive agents. [38283] [51778]
Measles/Mumps/Rubella Vaccines, MMR: (Major) Avoid concurrent use of live vaccines during treatment with 
tocilizumab due to potentially increased risk of infections; clinical safety of live vaccines during tocilizumab 
treatment has not been established. No data are available on the secondary transmission of infection from persons 
receiving live vaccines to patients receiving tocilizumab. The interval between live vaccinations and initiation of 
tocilizumab therapy should be in accordance with current vaccination guidelines regarding immunosuppressive 
agents. [38283] [51778]
Muromonab-CD3: (Major) Closely observe patients for signs of infection if immunosuppressive biologic agents such 
as Muromonab-CD3 are used concomitantly with tocilizumab. The use of tocilizumab with other biologic 
immunosuppressive agents has not been studied. Most patients taking tocilizumab who developed serious infections 
were taking concomitant immunosuppressives. [38283] [41935]
Niacin; Simvastatin: (Moderate) Utilize caution with concomitant use of tocilizumab and CYP3A4 substrate drugs, 
such as simvastatin, where a decrease in effectiveness is undesirable. Monitor lipid panels and adjust therapy as 
indicated. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 57% decrease in simvastatin 
exposure was noted 1 week after a single tocilizumab dose. In vitro, tocilizumab has the potential to affect expression 
of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Simvastatin 
is a CYP3A4 substrate. [38283]
Ofatumumab: (Major) Avoid the concomitant use of ofatumumab and tocilizumab; coadministration has not been 
studied and may result in additive immunosuppression and an increased risk of infection. [38283] [45566]
Omeprazole: (Minor) Concomitant use of tocilizumab and omeprazole may lead to a decrease in the efficacy of 
omeprazole. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 12 to 28% decrease in 
omeprazole exposure occurred 1 week after a single tocilizumab dose. In vitro, tocilizumab has the potential to affect 
expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 
Omeprazole is a substrate of both CYP2C19 and CYP3A4. [38283]
Omeprazole; Amoxicillin; Rifabutin: (Minor) Concomitant use of tocilizumab and omeprazole may lead to a decrease 
in the efficacy of omeprazole. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 12 to 
28% decrease in omeprazole exposure occurred 1 week after a single tocilizumab dose. In vitro, tocilizumab has the 
potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Omeprazole is a substrate of both CYP2C19 and CYP3A4. [38283]
Omeprazole; Sodium Bicarbonate: (Minor) Concomitant use of tocilizumab and omeprazole may lead to a decrease 
in the efficacy of omeprazole. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 12 to 
28% decrease in omeprazole exposure occurred 1 week after a single tocilizumab dose. In vitro, tocilizumab has the 
potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Omeprazole is a substrate of both CYP2C19 and CYP3A4. [38283]
Oral Contraceptives: (Moderate) Utilize caution with concomitant use of tocilizumab and CYP3A4 substrate drugs, 
such as combined hormonal oral contraceptives, where a decrease in effectiveness is undesirable. Inhibition of IL-6 
signaling by tocilizumab may restore CYP450 activities to higher levels leading to increased metabolism of drugs that 
are CYP450 substrates as compared to metabolism prior to treatment. This effect on CYP450 enzyme activity may 
persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. [38283]
Phenytoin: (Moderate) Monitor phenytoin concentrations and watch for decreased efficacy of phenytoin if 
coadministration with tocilizumab is necessary; adjust phenytoin dosage as necessary. Inhibition of IL-6 signaling by 
tocilizumab may restore CYP450 activities to higher levels leading to increased metabolism of drugs that are CYP450 
substrates compared to metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, 
such as phenytoin, may have fluctuations in drug levels and therapeutic effect when tocilizumab therapy is started or 
discontinued. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. In 
vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Phenytoin is a substrate of both CYP2C9 and CYP2C19 and narrow 
therapeutic index drug. [38283]
Pimozide: (Moderate) Monitor for an altered patient response to pimozide if coadministration with tocilizumab is 
necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment. Therefore, 
CYP450 substrates with a narrow therapeutic index, such as pimozide, may have fluctuations in drug levels and 
therapeutic effect when tocilizumab therapy is started or discontinued. This effect on CYP450 enzyme activity may 
persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Pimozide is a 
substrate of both CYP2D6 and CYP3A4 and narrow therapeutic index drug. [38283]
Quinidine: (Moderate) Monitor quinidine levels and adjust the dose of quinidine as appropriate if coadministration 
with tocilizumab is necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to 
treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as quinidine, may have fluctuations in 
drug levels and therapeutic effect when tocilizumab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to 
affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Quinidine is a CYP3A4 substrate and narrow therapeutic index drug. [38283]
Rituximab: (Major) Avoid the concomitant use of rituximab and tocilizumab; coadministration has not been studied 
and may result in additive immunosuppression and an increased risk of infection. [38283] [49773]
Rituximab; Hyaluronidase: (Major) Avoid the concomitant use of rituximab and tocilizumab; coadministration has 
not been studied and may result in additive immunosuppression and an increased risk of infection. [38283] [49773]
Rivaroxaban: (Moderate) Monitor for a decrease in efficacy of rivaroxaban if used with tocilizumab. Until more data 
are available, consider using an anticoagulant without dependence on CYP450 enzymes for metabolism (e.g., 
heparins, edoxaban). The formation of CYP450 enzymes may be suppressed by increased concentrations of cytokines 
such as IL-6 during chronic inflammation. It is expected that the activity of CYP450 enzymes could increase to 
normal concentrations during treatment with an IL-6 antagonist such as tocilizumab; these effects on CYP450 
enzyme activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to 
affect expression of multiple CYP enzymes [including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4]. Rivaroxaban is a substrate for CYP3A4/5. [38283] [44854] [65210]
Rotavirus Vaccine: (Major) Avoid concurrent use of live vaccines during treatment with tocilizumab due to 
potentially increased risk of infections; clinical safety of live vaccines during tocilizumab treatment has not been 
established. No data are available on the secondary transmission of infection from persons receiving live vaccines to 
patients receiving tocilizumab. The interval between live vaccinations and initiation of tocilizumab therapy should be 
in accordance with current vaccination guidelines regarding immunosuppressive agents. [38283] [51778]
Rubella Virus Vaccine Live: (Major) Avoid concurrent use of live vaccines during treatment with tocilizumab due to 
potentially increased risk of infections; clinical safety of live vaccines during tocilizumab treatment has not been 
established. No data are available on the secondary transmission of infection from persons receiving live vaccines to 
patients receiving tocilizumab. The interval between live vaccinations and initiation of tocilizumab therapy should be 
in accordance with current vaccination guidelines regarding immunosuppressive agents. [38283] [51778]
Sarilumab: (Major) Avoid using sarilumab with other biological DMARDs, such as tocilizumab; coadministration has 
not been studied and may result in additive immunosuppression and increased risk of infection. [38283] [61976]
Secukinumab: (Major) Avoid using tocilizumab with other biological DMARDs, such as secukinumab; 
coadministration has not been studied and may result in additive immunosuppression and increased risk of infection. 
[38283]
Simvastatin: (Moderate) Utilize caution with concomitant use of tocilizumab and CYP3A4 substrate drugs, such as 
simvastatin, where a decrease in effectiveness is undesirable. Monitor lipid panels and adjust therapy as indicated. 
Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect on 
CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 57% decrease in simvastatin 
exposure was noted 1 week after a single tocilizumab dose. In vitro, tocilizumab has the potential to affect expression 
of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Simvastatin 
is a CYP3A4 substrate. [38283]
Simvastatin; Sitagliptin: (Moderate) Utilize caution with concomitant use of tocilizumab and CYP3A4 substrate 
drugs, such as simvastatin, where a decrease in effectiveness is undesirable. Monitor lipid panels and adjust therapy 
as indicated. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. This effect 
on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. A 57% decrease in simvastatin 
exposure was noted 1 week after a single tocilizumab dose. In vitro, tocilizumab has the potential to affect expression 
of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Simvastatin 
is a CYP3A4 substrate. [38283]
Sirolimus: (Moderate) Monitor sirolimus levels and adjust the dose of sirolimus as appropriate if coadministration 
with tocilizumab is necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to 
treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as sirolimus, may have fluctuations in 
drug levels and therapeutic effect when tocilizumab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to 
affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Sirolimus is a CYP3A4 substrate and narrow therapeutic index drug. [38283]
Smallpox and Monkeypox Vaccine, Live, Nonreplicating: (Major) Avoid concurrent use of live vaccines during 
treatment with tocilizumab due to potentially increased risk of infections; clinical safety of live vaccines during 
tocilizumab treatment has not been established. No data are available on the secondary transmission of infection from 
persons receiving live vaccines to patients receiving tocilizumab. The interval between live vaccinations and initiation 
of tocilizumab therapy should be in accordance with current vaccination guidelines regarding immunosuppressive 
agents. [38283] [51778]
Smallpox Vaccine, Vaccinia Vaccine: (Major) Avoid concurrent use of live vaccines during treatment with 
tocilizumab due to potentially increased risk of infections; clinical safety of live vaccines during tocilizumab 
treatment has not been established. No data are available on the secondary transmission of infection from persons 
receiving live vaccines to patients receiving tocilizumab. The interval between live vaccinations and initiation of 
tocilizumab therapy should be in accordance with current vaccination guidelines regarding immunosuppressive 
agents. [38283] [51778]
Tacrolimus: (Moderate) Monitor tacrolimus levels and adjust the dose of tacrolimus as appropriate if coadministration 
with tocilizumab is necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to 
treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as tacrolimus, may have fluctuations 
in drug levels and therapeutic effect when tocilizumab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to 
affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Tacrolimus is a CYP3A4 substrate and narrow therapeutic index drug. [38283]
Theophylline, Aminophylline: (Moderate) Monitor drug concentrations and watch for decreased efficacy of 
aminophylline or theophylline if coadministration with tocilizumab is necessary; a dosage increase of these 
methylxanthines may be necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to 
higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to 
treatment. Therefore, CYP450 substrates with a narrow therapeutic index may have fluctuations in drug levels and 
therapeutic effect when tocilizumab therapy is started or discontinued. This effect on CYP450 enzyme activity may 
persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Aminophylline 
and Theophylline are CYP1A2 substrates and narrow therapeutic index drugs. [38283]
Thioridazine: (Moderate) Monitor for an altered patient response to thioridazine if coadministration with tocilizumab 
is necessary. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment. Therefore, 
CYP450 substrates with a narrow therapeutic index, such as thioridazine, may have fluctuations in drug levels and 
therapeutic effect when tocilizumab therapy is started or discontinued. This effect on CYP450 enzyme activity may 
persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Thioridazine is 
a CYP2D6 substrate and narrow therapeutic index drug. [38283]
Tizanidine: (Moderate) Monitor for reduced efficacy of tizanidine if coadministered with tocilizumab. An adjustment 
of tizanidine dose may be required. Inhibition of IL-6 signaling by tocilizumab may restore CYP450 activities to 
higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to 
treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as tizanidine, may have fluctuations in 
drug levels and therapeutic effect when tocilizumab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping tocilizumab. In vitro, tocilizumab has the potential to 
affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Tizanidine is a CYP1A2 substrate and narrow therapeutic index drug. [38283]
Tofacitinib: (Major) Avoid the concomitant use of tocilizumab with other biological DMARDs such as tofacitinib; 
coadministration has not been studied and may result in additive immunosuppression and increased risk of infection. 
[38283] [52315]
Tumor Necrosis Factor modifiers: (Major) Avoid the concomitant use of tocilizumab with biological DMARDs, such 
as tumor necrosis factor (TNF) modifiers; coadministration has not been studied and may result in additive 
immunosuppression and increased risk of infection. [38283]
Typhoid Vaccine: (Major) Avoid concurrent use of live vaccines during treatment with tocilizumab due to potentially 
increased risk of infections; clinical safety of live vaccines during tocilizumab treatment has not been established. No 
data are available on the secondary transmission of infection from persons receiving live vaccines to patients 
receiving tocilizumab. The interval between live vaccinations and initiation of tocilizumab therapy should be in 
accordance with current vaccination guidelines regarding immunosuppressive agents. [38283] [51778]
Upadacitinib: (Major) Avoid the concomitant use of tocilizumab with other biological DMARDs such as 
upadacitinib; coadministration has not been studied and may result in additive immunosuppression and increased risk 
of infection. [38283] [64572]
Ustekinumab: (Major) Avoid the concomitant use of tocilizumab with other biological DMARDs such as 
ustekinumab; coadministration has not been studied and may result in additive immunosuppression and increased risk 
of infection. [38283]
Varicella-Zoster Virus Vaccine, Live: (Major) Avoid concurrent use of live vaccines during treatment with 
tocilizumab due to potentially increased risk of infections; clinical safety of live vaccines during tocilizumab 
treatment has not been established. No data are available on the secondary transmission of infection from persons 
receiving live vaccines to patients receiving tocilizumab. The interval between live vaccinations and initiation of 
tocilizumab therapy should be in accordance with current vaccination guidelines regarding immunosuppressive 
agents. [38283] [51778]
Warfarin: (Moderate) Monitor the INR if tocilizumab is coadministered with warfarin due to the potential for 
decreased warfarin efficacy; adjust the dose of warfarin as necessary. Inhibition of IL-6 signaling by tocilizumab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates as 
compared to metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as 
warfarin, may have fluctuations in drug levels and therapeutic effect when tocilizumab therapy is started or 
discontinued. This effect on CYP450 enzyme activity may persist for several weeks after stopping tocilizumab. 
[28549] [38283]
Yellow Fever Vaccine, Live: (Major) Avoid concurrent use of live vaccines during treatment with tocilizumab due to 
potentially increased risk of infections; clinical safety of live vaccines during tocilizumab treatment has not been 
established. No data are available on the secondary transmission of infection from persons receiving live vaccines to 
patients receiving tocilizumab. The interval between live vaccinations and initiation of tocilizumab therapy should be 
in accordance with current vaccination guidelines regarding immunosuppressive agents. [38283] [51778]
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Monitoring Parameters
• CBC with differential
• LFTs
• platelet count
• serum lipid profile
IV Compatibility of Tocilizumab with:
Legend
 = Compatible
 = Incompatible
 = Results uncertain, variable or dependent on conditions
ND = No Data Available
From Trissel's 2™ Clinical Pharmaceutics Database 
Admixture Syringe Y-Site Administration For Dilution
Normal saline- Sodium chloride 0.9% ND ND ND 
Sodium chloride 0.45% ND ND ND 
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